WO2016169261A1 - 一种新的重组双功能融合蛋白及其制备和应用 - Google Patents

一种新的重组双功能融合蛋白及其制备和应用 Download PDF

Info

Publication number
WO2016169261A1
WO2016169261A1 PCT/CN2015/094739 CN2015094739W WO2016169261A1 WO 2016169261 A1 WO2016169261 A1 WO 2016169261A1 CN 2015094739 W CN2015094739 W CN 2015094739W WO 2016169261 A1 WO2016169261 A1 WO 2016169261A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
protein
bifunctional fusion
cells
recombinant bifunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/094739
Other languages
English (en)
French (fr)
Inventor
田文志
景德强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immuneonco Biopharmaceuticals Shanghai Inc
Original Assignee
Immuneonco Biopharmaceuticals Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuneonco Biopharmaceuticals Shanghai Inc filed Critical Immuneonco Biopharmaceuticals Shanghai Inc
Priority to EP15889744.7A priority Critical patent/EP3287470B1/en
Priority to US15/566,724 priority patent/US10800821B2/en
Priority to ES15889744T priority patent/ES2959132T3/es
Priority to JP2017552177A priority patent/JP6682554B2/ja
Publication of WO2016169261A1 publication Critical patent/WO2016169261A1/zh
Anticipated expiration legal-status Critical
Priority to US16/905,262 priority patent/US20210024598A1/en
Priority to US17/412,445 priority patent/US20210388043A1/en
Priority to US18/492,925 priority patent/US20250127855A1/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Definitions

  • the invention relates to a recombinant bifunctional fusion protein and a preparation method and application thereof, in particular to the application thereof in tumor treatment.
  • tumor cells In order to accelerate their growth, tumor cells often "invent” some ways to evade host immune surveillance of tumor cells.
  • the known routes include three types: 1) immune surveillance to evade T lymphocytes. Tumor cells often express membrane proteins PD-L1 and PD-L2, while PD-L1/PD-L2 binds to PD-1 on the surface of T cell membranes and induces T cell apoptosis. 2) Avoid immune surveillance of natural killer (NK) cells. On the cell membrane of NK cells, there is a protein NKG2D that activates NK cells. When NKG2D binds to MICA/MICB on the tumor cell membrane, it can activate the killing of tumor cells by NK cells.
  • NK natural killer
  • tumor cells themselves have a mechanism to cause MICA/MICB to detach from the cell membrane, and the shed MICA/MICB binds to NKG2D on the surface of NK cell membrane, thereby blocking the binding of NKG2D to MICA/MICB on the surface of tumor cell membrane.
  • M ⁇ macrophages
  • Almost all tumor cells express CD47 on the surface of their cell membrane, and CD47 binds to the signal-regulated protein (SIRP ⁇ ) on the surface of macrophage (M ⁇ ) membrane, thereby inducing an inhibitory signal and inhibiting macrophage (M ⁇ ).
  • SIRP ⁇ signal-regulated protein
  • M ⁇ macrophage
  • in order to eliminate the tumor we must start from these ways and combine other means to design effective drugs.
  • SIRP Signaling protein
  • CD172a family members
  • SIRP ⁇ CD172b
  • SIRP ⁇ CD172g
  • Fig. 1A The outer end of the membrane contains three immunoglobulin (Ig)-like regions, of which the first region belongs to the Ig-V region and the second and third regions belong to the Ig-C region.
  • Ig immunoglobulin
  • the intramembranous region of SIRP ⁇ (CD172a) contains two inhibitory signal domains that transmit an inhibitory signal and inhibit the corresponding function of the cell.
  • SIRP ⁇ IL-12
  • DAP12 adaptor protein
  • SIRPs are mainly expressed in macrophages (M ⁇ ), dendritic cells (DC), and neuronal cells.
  • CD47 is also a transmembrane glycoprotein that belongs to the immunoglobulin superfamily and is expressed on almost all cell surfaces including red blood cells.
  • Ligands for CD47 include adhesion factors (integrins), thrombospondin-1, and signal regulatory proteins (SIRPs).
  • CD47 has a variety of biological functions, including cell migration, T cells, dendritic cell activation, axonal development, and the like.
  • CD47 inhibits macrophage phagocytosis by interacting with SIRP ⁇ . In this way, CD47 transmits a so-called "Don't eat me" signal that protects normal cells such as blood cells from being phagocytosed by macrophages.
  • CD47 chronic myeloid leukemia cells
  • ALL acute lymphoblastic leukemia cells
  • NHL non-Hodgkin's lymphoma
  • MM multiple myeloma
  • Fc receptors are proteins found on the surface of certain cells.
  • the cells include: B lymphocytes, follicular dendritic cells, natural killer cells, macrophages, neutrophils, eosinophils, basophils, mast cells, which contribute to the protective function of the immune system. cell.
  • Fc receptors bind to antibodies attached to infected cells, invading pathogens or cancer cells and stimulate phagocytic or cytotoxic cells, thereby allowing for antibody-mediated phagocytosis or antibody-dependent cell-mediated cytotoxicity. Destroy microorganisms, infected cells or cancer cells.
  • the invention relates to a genetic recombinant fusion protein, which can achieve the purpose of eliminating tumor by two mechanisms, one is to block the inhibition signal of macrophage induced by tumor cells, and the other is to directly activate the phagocytosis of macrophages.
  • the protein is ligated with the Fc fragment of human IgG1 (SIRP ⁇ D1-Fc) by the first Ig-like region (SIRP ⁇ D1) of the extramembranous end of the human signal-regulatory proteins alpha (SIRP ⁇ ).
  • the protein belongs to a homodimer, a 90kDa fusion protein consisting of the first region of the outer membrane of SIRP ⁇ (Domain1, D1) and the Fc fragment of human IgG (SIRP ⁇ D1-Fc), recombined with the entire outer membrane.
  • the protein (SIRP ⁇ -Fc) has higher target binding activity than the protein.
  • the present inventors have further found that removal of the glycosylation site (N89A) of the D1 region of the outer end of the SIRP ⁇ membrane can further increase the binding activity of the target; while retaining the binding activity of the Fc to the Fc receptor can greatly increase the anti-tumor of SIRP ⁇ D1-Fc. active.
  • the stable expression cell line of the protein was prepared by Chinese hamster ovary cells (CHO), and the protein was prepared by shaking culture.
  • CHO Chinese hamster ovary cells
  • the protein was prepared by shaking culture.
  • In vitro experiments confirmed that the protein binds to CD47 and the binding activity is significantly increased compared to SIRP ⁇ -Fc.
  • the glycosylation site "NIT" in SIRP ⁇ D1 is removed by genetic modification (N89A) (SIRP ⁇ D1-Fc(N89A), designated as HY03M)
  • the binding activity of HY03M to the target CD47 is further enhanced.
  • HY03MM 192th amino acid of the Fc region is mutated from aspartic acid to alanine (D192A) (SIRP ⁇ D1-Fc (N89A/D192A), named HY03MM), then HY03MM and Fc receptors (CD16a, CD32, CD64) The binding activity is significantly reduced.
  • the anti-tumor effect of HY03M was studied in a mouse model of human acute lymphoblastic leukemia and acute promyelocytic leukemia. The results showed that HY03M has strong anti-tumor activity. The growth of tumor cells was completely completed in HY03M-treated mice. Inhibition, tumors have not been detected in individual mice.
  • the recombinant protein of the invention is HY03M (SEQ ID NO.: 5, SEQ ID NO.: 6).
  • HY03M has strong anti-tumor activity, and its principle of action includes two aspects: 1) by blocking the interaction of CD47-SIRPa; 2) activating macrophages by binding of Fc to Fc receptor; HY03M can be used to treat various targets Point positive tumor.
  • the invention also provides a nucleic acid molecule encoding a recombinant bifunctional fusion protein, an expression vector for expressing the protein, a method for preparing a modified protein, and a method for treating a disease overexpressing CD47.
  • the recombinant bifunctional fusion protein of the invention comprises an Ig-like region of the outer membrane of a signal regulatory protein (SIRP), linked to an Fc fragment of human IgG1, wherein the protein binds to CD47, thereby blocking CD47 and giant
  • SIRP signal regulatory protein
  • the signal-modulating protein in the recombinant bi-functional fusion protein is SIRP ⁇
  • the Ig-like region at the outer end of the signal-regulating protein membrane is SIRP ⁇ D1.
  • a recombinant bifunctional fusion protein of the invention comprises an Fc fragment that is part of an immunoglobulin molecule.
  • the Fc fragment does not have an antigen binding site, it contributes to some effector functions, such as facilitating binding of the antibody to the Fc receptor and binding to the complement system on a variety of cells.
  • the Fc fragment is an Fc fragment of IgGl.
  • a recombinant bifunctional fusion protein of the invention comprises an amino acid sequence at least 95% similar to SEQ ID NO.: 6. In one embodiment, the amino acid sequence of the recombinant bifunctional fusion protein of the invention has at least 98% similarity to SEQ ID NO.: 6. In one embodiment, the amino acid sequence of the recombinant bifunctional fusion protein of the invention has at least 99% similarity to SEQ ID NO.: 6. In one embodiment, the recombinant bifunctional fusion protein of the invention comprises the amino acid sequence of SEQ ID NO.: 6.
  • the invention provides a polynucleotide molecule encoding a recombinant bifunctional fusion protein of the invention comprising an Ig-like region at the outer portion of a signal-regulated protein (SIRP) membrane, linked to an Fc fragment of human IgG1 Wherein the protein binds to CD47, thereby blocking the binding of CD47 to the surface of the macrophage SIRP, and activating the phagocytosis of the tumor cells by the macrophage.
  • SIRP signal-regulated protein
  • a polynucleotide molecule of the invention encodes a recombinant bifunctional fusion protein comprising SIRP ⁇ , preferably SIRP ⁇ D1.
  • a polynucleotide molecule of the invention encodes a recombinant bifunctional fusion protein comprising an Fc fragment of Ig, preferably an Fc fragment of human IgGl.
  • a polynucleotide molecule of the invention encodes a recombinant bifunctional fusion protein comprising an amino acid sequence at least 95% identical to SEQ ID NO.: 6. In one embodiment, the amino acid sequence of the recombinant bifunctional fusion protein of the invention has at least 98% similarity to SEQ ID NO.: 6. In one embodiment, the amino acid sequence of the recombinant bifunctional fusion protein of the invention has at least 99% similarity to SEQ ID NO.: 6. In one embodiment, a polynucleotide molecule of the invention encodes a recombinant bifunctional fusion protein comprising the amino acid sequence of SEQ ID NO.: 6.
  • the invention provides an expression vector comprising a polynucleotide molecule of the invention,
  • the polynucleotide molecule encodes a recombinant bifunctional fusion protein.
  • the invention provides a host cell comprising an expression vector of the invention.
  • the invention provides a pharmaceutical composition comprising a recombinant bifunctional fusion protein of the invention and at least one adjuvant.
  • the invention provides a method of treating a condition caused by overexpression of CD47 comprising administering to a patient or subject a therapeutically effective amount of a pharmaceutical composition of the invention.
  • the invention provides a recombinant bifunctional fusion protein for use in the preparation of a disease caused by overexpression of CD47.
  • the disease for treating the method of the invention is selected from the group consisting of myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and non-Hodgkin's lymphoma (NHL).
  • AML myeloid leukemia
  • CML chronic myeloid leukemia
  • ALL acute lymphocytic leukemia
  • NDL non-Hodgkin's lymphoma
  • the invention provides a method for treating Crohn's disease, myeloid asthma, and rheumatoid arthritis.
  • Figure 1 is a schematic diagram showing the molecular structure and operation of SIRPs and SIRP ⁇ D1-Fc.
  • Figure 2 is a SIRP ⁇ -Fc nucleotide and amino acid sequence.
  • Figure 3 is a SIRP ⁇ D1-Fc nucleotide and amino acid sequence.
  • Figure 4 is the HY03M nucleotide and amino acid sequence.
  • Figure 5 is the HY03MM nucleotide and amino acid sequence.
  • Figure 6 is a SDS-PAGE electropherogram of four fusion proteins.
  • Figure 7 shows the results of analysis of the binding activity of SIRP ⁇ -Fc and SIRP ⁇ D1-Fc to PC-3 cells.
  • Figure 8 is an analysis of the target blocking activity of the unlabeled protein against the fluorescently labeled SIRP ⁇ -Fc.
  • Figure 9 is the Fc receptor binding activity and induction of phagocytic activity of macrophages on tumor cells.
  • Figure 10 is the in vivo efficacy of four fusion proteins on tumors.
  • the invention relates to a genetic recombinant fusion protein, which can achieve the purpose of eliminating tumor by two mechanisms, one is to block the inhibition signal of macrophage induced by tumor cells, and the other is to directly activate the phagocytosis of macrophages.
  • the protein is ligated with the Fc fragment of human IgG1 (SIRP ⁇ D1-Fc) by the first Ig-like region (SIRP ⁇ D1) of the extramembranous end of the human signal-regulatory proteins alpha (SIRP ⁇ ).
  • This protein belongs to a homodimer and has a molecular weight of 90 kDa.
  • HY03MM 211th amino acid of the Fc region is mutated from aspartic acid to alanine (D192A) (SIRP ⁇ D1-Fc (N89A/D192A), named HY03MM), then HY03MM and Fc receptors (CD16a, CD32, The binding activity of CD64) is significantly reduced.
  • DI192A alanine
  • HY03MM and Fc receptors CD16a, CD32, The binding activity of CD64
  • HY03M Fc is involved in anti-tumor activity
  • HY03MM has obvious tumor growth inhibitory activity, its activity is greatly reduced compared with HY03M, suggesting that Fc region participates in antitumor activity by binding to Fc receptor of macrophages.
  • the fusion protein of the present invention comprises two parts, a target binding fragment (i.e., SIRP ⁇ D1) and an Fc fragment.
  • the recombinant bifunctional fusion proteins of the invention can also be combined with non-polypeptide molecules to achieve desirable properties, such as reduced degradation and/or increased half-life, reduced toxicity, reduced immunogenicity, and/or increased biological activity.
  • non-polypeptide molecules include, but are not limited to, polymers such as polyethylene glycol (PEG), polylysine, dextran; blood lipids; cholesterol groups (such as hormones); carbohydrates, or oligosaccharide molecules.
  • the Fc fragment can be 232 amino acids in length, including one cysteine in the hinge region, two cysteines in the CH2 region, and two cysteines in the CH3 region.
  • the cysteine in the hinge region is used to form a disulfide bond between the two monomers, thereby producing a dimer, and the cystine in the CH2 region and the CH3 region can form an intra-bond disulfide bond to stabilize the protein.
  • an Ig region of the outer end of a SIPR (SIRP ⁇ , SIRP ⁇ ) membrane capable of binding to CD47 can be used in the fusion protein.
  • human sequences are useful in the treatment of human cancer because proteins or peptides derived from non-human animals are strongly immunogenic and cause allergies and other side effects.
  • proteins or peptides derived from non-human animals are strongly immunogenic and cause allergies and other side effects.
  • other animal proteins or peptides can be used for other application purposes of the invention.
  • the signal-modulating protein in the recombinant bi-functional fusion protein of the invention is SIRP ⁇ .
  • the Ig-like region at the outer end of the signal-regulating protein membrane is SIRP ⁇ D1.
  • Immunoglobulins include IgG, IgA, IgM, IgD, and IgA, with IgG being the most abundant and relatively stable.
  • An Fc fragment of IgG, an Fc fragment of IgG1, and an Fc fragment of human IgG1 are preferred because these Fc fragments exhibit the highest binding to Staphylococcus Protein A and are thus easily purified.
  • a recombinant bifunctional fusion protein of the invention comprises a first Ig-like region of the outer portion of the human SIRP ⁇ membrane, joined by an Fc fragment of human IgG1.
  • the amino acid sequence of the recombinant bifunctional fusion protein of the invention is as shown in Figure 4B (SEQ ID NO.: 6).
  • the recombinant bifunctional fusion protein comprises a polypeptide of the sequence set forth in SEQ ID NO.: 6.
  • the amino acid sequence of the polypeptide has at least 80%, 85%, 90%, 95%, 98%, or 99% similarity to SEQ ID NO.: 6, wherein the polypeptide is capable of interacting with CD47 Binding and inhibiting the growth of tumor cells.
  • Another aspect of the invention provides an isolated nucleic acid molecule comprising a polynucleotide encoding a recombinant bifunctional fusion protein comprising a polypeptide of the sequence set forth in SEQ ID NO.: 6.
  • the polypeptide has an amino acid sequence of at least 80%, 85%, 90% with SEQ ID NO.: A similarity of 95%, 98% or 99%, wherein the polypeptide is capable of binding to CD47 and inhibiting the growth of tumor cells.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the aforementioned recombinant bifunctional fusion protein and at least one pharmaceutically acceptable excipient.
  • One or more carriers or excipients may also be included in the pharmaceutical composition as desired.
  • the carrier includes diluents, excipients, bulking agents, binders, wetting agents, disintegrating agents, absorption enhancers, surfactants, adsorption carriers, lubricants, and the like, which are commonly found in pharmacy.
  • compositions comprise a therapeutically or prophylactically effective amount of a polypeptide or protein in admixture with a pharmaceutically acceptable material and a physiologically acceptable formulation.
  • the pharmaceutical composition may include a formulation substance for modification, maintenance or preservation, for example, pH, osmotic pressure, viscosity, transparency, color, odor, sterility, order retention, stability, dissolution or release rate, combination Adsorption and penetration of matter.
  • Suitable formulations of materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine and lysine); antibacterial agents; antioxidants (such as ascorbic acid, sodium sulfite or sodium bisulfite); Buffering agents (such as boric acid, ammonium bicarbonate, Tris-HCl, citrate, phosphate, other organic acids); bulking agents (such as mannitol, glycine), chelating agents (such as ethylenediaminetetraacetic acid (EDTA)); Complexing agents (such as caffeine, polyvinylpyrrolidone, ⁇ -cyclodextrin or hydroxypropyl- ⁇ -cyclodextrin); fillers; monosaccharides; disaccharides and other carbohydrates (such as glucose, mannose, or dextrin) ); protein (such as serum albumin, gelatin or immunoglobulin); coloring; seasonings and diluents; emulsifiers
  • a suitable composition may be water for injection, physiological saline.
  • the primary carrier in the pharmaceutical composition may be aqueous or non-aqueous.
  • a suitable carrier can be water for injection, saline or artificial cerebrospinal fluid, supplemented by other common injectable materials.
  • the carrier may be a neutral buffer solution or physiological saline mixed with serum albumin.
  • Another typical pharmaceutical composition comprises a Tris buffer, or an acetate buffer, which may further comprise sorbitol or a suitable alternative.
  • the composition can be prepared by mixing a selected composition of the desired purity with an optional formulation (Remington's Pharmaceutical Sciences, supra) in the form of a lyophilized cake or aqueous solution.
  • the therapeutic compositions can be formulated into lyophilizates using suitable excipients such as sucrose.
  • the formulation can be delivered by various methods, for example, by inhalation therapy, orally or by injection.
  • parenteral administration is considered, the pharmaceutical composition of the present invention may be in the form of a parenterally acceptable aqueous solution.
  • the desired polypeptides in a pharmaceutically acceptable carrier.
  • a particularly suitable parenteral injection vehicle is sterile distilled water wherein the polypeptide is prepared in a sterile, isotonic solution suitable for storage.
  • Another preparation comprises the desired molecule and a preparation such as injection microspheres, biological microparticles, polymer (polylactic acid, polyglycolic acid), beads, or liposomes for sustained release and sustained release of the product. Release, followed by delivery by depot injection.
  • Hyaluronic acid can also be used, which promotes sustained release duration in the blood circulation.
  • Other suitable means of introducing a molecule include an implantable drug delivery device.
  • the pharmaceutical preparation suitable for administration by injection can be prepared in the form of an aqueous solution, preferably a physiologically compatible buffer such as Hanks' solution, Ringer's solution, Or physiological buffer.
  • the aqueous suspension for injection may contain substances which increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran.
  • the active compound suspension can be prepared in a suitable oily injection suspension.
  • Suitable fat-soluble solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate, triglycerides, or liposomes.
  • Non-lipid cationic amino polymers are also useful for delivery.
  • the suspension may also contain suitable stabilizers or formulations to increase the water solubility of the compound and allow for the preparation of high concentration solutions.
  • a pharmaceutical composition can be formulated for inhalation.
  • the inhalation solution can also be prepared in the form of a propellant for aerosol delivery.
  • the solution can be atomized.
  • Administration of the lungs is further described in PCT Application No. PCT/US94/001875, which describes the pulmonary administration of chemically modified proteins.
  • the molecules administered in this manner may or may not be prepared with a solid dosage form such as a carrier conventionally used in tablets and capsules.
  • a solid dosage form such as a carrier conventionally used in tablets and capsules.
  • the capsules can be designed to release the active substance in the gastrointestinal tract.
  • Additives may be included to promote absorption of the therapeutic molecule. Diluents, perfumes, low melting waxes, vegetable oils, lubricating oils, suspending agents, tablet disintegrating agents and binders can also be used.
  • Oral pharmaceutical compositions can be prepared using pharmaceutically acceptable carriers suitable for oral administration which are well known in the art. Such a carrier allows the pharmaceutical composition to be administered to a patient in the form of tablets, pills, granules, capsules, liquids, gels, syrups, slurries, suspensions and the like.
  • Oral formulations can be obtained by combining the active compound with a solid excipient and processing a mixture of the particles (optional, after milling) to obtain a tablet or dragee core.
  • auxiliaries can be added if needed.
  • Suitable excipients include carbohydrate or protein fillers such as sugars including lactose, sucrose, mannitol, sorbitol; corn, wheat, rice, potato starch, or other plants; cellulose, such as methylcellulose, hydroxy Propyl methylcellulose, or sodium carboxymethylcellulose; viscose, including gum arabic; and proteins such as gelatin and collagen.
  • a disintegrating or dissolving agent such as cross-linked polyvinylpyrrolidone, agar, and alginic acid or a salt thereof such as sodium alginate may be added.
  • the dragee core may be combined with a suitable coating, such as a concentrated sugar solution, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbomer gel, polyethylene glycol, and/or titanium dioxide, lacquer solvent, and A suitable organic solvent or solvent mixture.
  • a suitable coating such as a concentrated sugar solution, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbomer gel, polyethylene glycol, and/or titanium dioxide, lacquer solvent, and A suitable organic solvent or solvent mixture.
  • Dyestuffs or pigments may be added to the tablets or dragee cores for product identification or to distinguish the amount of active compound, i.e., the dosage.
  • Oral pharmaceutical preparations also include soft, closed push-fit capsules made of gelatin, as well as coatings such as glycerin or sorbitol.
  • the push-fit capsules contain the active ingredient in admixture with fillers and binders such as lactose and starch, lubricants such as talc, magnesium stearate, and, optionally, stabilizers.
  • fillers and binders such as lactose and starch
  • lubricants such as talc, magnesium stearate
  • stabilizers Activated in soft capsules
  • the compound can be dissolved or suspended in a suitable liquid, such as a fatty oil, a liquid, or a liquid polyethylene glycol, with or without the addition of a stabilizer.
  • sustained release and sustained release formulations include polypeptides for sustained release and sustained release formulations.
  • sustained release and sustained release formulations are also known to those skilled in the art, such as liposome carriers, biological microparticles or porous beads, and long acting injectables.
  • PCT/US93/00829 describes the release of porous polymer microparticles for controlling the delivery of a pharmaceutical composition.
  • sustained release formulations include semi-permeable membrane polymer matrices in the form of articles, in the form of microparticles, such as films or microcapsules.
  • the sustained release matrix may include polyester, hydrogel, polylactic acid (Langer et al., J. Biomed. Mater.
  • Sustained release compositions also include liposomes, which can be prepared by several methods known in the art. See, for example, Eppstein et al., PNAS (USA), 82: 3688 (1985); EP 36,676; EP 88,046; EP 143,949.
  • compositions for in vivo administration must generally be sterile. This can be achieved by filtration through a sterile filtration membrane. When the composition is lyophilized, the method can be carried out before or after sterilization or lyophilization.
  • Compositions for parenteral administration may be stored in lyophilized form or in the form of a solution.
  • parenteral compositions are typically placed in a container having a sterile access port, such as an IV bag or bottle with a stopper that can be pierced by a hypodermic needle.
  • the pharmaceutical composition can be stored in a sterile vial in the form of a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder.
  • Such formulations may be stored in a form ready for use prior to administration or in a form that requires reconstitution (e.g., lyophilization).
  • the invention relates to a kit for preparing a single dose administration unit.
  • the kit may comprise a first container having a dried protein and a second container having an aqueous formulation.
  • the invention also encompasses single, multi-chamber pre-filled syringes (e.g., liquid syringes and lyosyringes).
  • the effective amount of the pharmaceutical composition for treatment depends on, for example, the therapeutic environment and the subject. Those skilled in the art will appreciate that appropriate dosage levels for treatment are partially distinguished from delivery of the molecule, indicators of polypeptide use, route of administration, and size of the patient (body weight, body surface or organ size) and conditions (age and general health). ). Therefore, the clinician can titrate the dose and modify the route of administration to obtain the best therapeutic effect.
  • a typical dosage range is from about 0.1 mg/kg to 100 mg/kg or more, depending on the factors mentioned above.
  • the polypeptide composition may preferably be injected or intravenously.
  • the long acting pharmaceutical composition can be administered every three to four days, every week or two, depending on the half life and the clearance rate of the particular formulation.
  • the frequency of administration will depend on the polypeptide pharmacokinetic parameters of the formulation used.
  • the composition is administered until the amount achieves the desired effect.
  • the composition may be administered as a single dose or multiple doses (at the same or different concentrations/doses) over time or as a continuous injection.
  • the appropriate dose can be further adjusted.
  • the appropriate dose can be determined by using appropriate dose-response data.
  • the route of administration of the pharmaceutical composition is known, such as oral administration, by intravenous, intraperitoneal, brain (brain parenchyma), lateral ventricle, muscle, internal ophthalmic artery, portal vein, intralesional route, intramedullary, intrathecal injection, ventricle , transdermal, subcutaneous, or intraperitoneal injection; and intranasal, enteral, topical, sublingual, urethral, vaginal, or rectal means, through a sustained release system or through an implant device.
  • the composition can pass, if desired A single rapid intravenous or continuous infusion is administered or injected through an infusion device.
  • the composition can be administered topically, by adsorption or encapsulation of the desired molecule via a membrane, sponge implant, or other suitable material.
  • a membrane, sponge implant, or other suitable material If an implant device is used, the device can be transplanted to any suitable tissue or organ and the desired molecule can be delivered by diffusion, timed release pellets, or continuous administration.
  • a recombinant bifunctional fusion protein of the invention can be delivered by transplantation of certain cells that are transgenic by the methods described herein to express and secrete the polypeptide.
  • These cells may be cells of animals or humans and may be autologous, allogeneic or heterologous. Alternatively, it may be an immortalized cell. To reduce the chance of an immune response, these cells are blocked to avoid infiltration of surrounding tissue.
  • the encapsulating material is typically a biocompatible, semi-permeable polymeric shell or membrane that allows for the release of the polypeptide product, but can prevent damage to the cell by the patient's immune system or other disruptive factors of the surrounding tissue.
  • a nucleic acid molecule encoding a recombinant bifunctional fusion protein of the invention, or a derivative thereof is introduced directly into a subject.
  • a nucleic acid encodes a bifunctional fusion protein
  • a nucleic acid sequence encoding a recombinant bifunctional fusion protein of the present invention is introduced into a target cell by local injection of a nucleic acid, and a delivery vector such as an adeno-associated virus vector can be optionally used.
  • Alternative viral vectors include, but are not limited to, retroviruses, adenoviruses, herpes simplex viruses, and papillomavirus vectors.
  • the physical delivery of the viral vector in vivo can be by local injection of the desired nucleic acid construct or other delivery vector containing the appropriate nucleic acid sequence, liposome-mediated transfer, direct jetting (naked DNA), or microprojectile bombardment (gene gun) to realise.
  • compositions of the invention may be used alone or in combination with other therapeutic agents to increase efficacy or reduce potential side effects.
  • Another object of the present invention is to provide a method for preparing the recombinant bifunctional fusion protein and a pharmaceutical composition comprising the same.
  • the method comprises: (1) providing a polynucleotide molecule for encoding; (2) constructing an expression vector comprising the polynucleotide molecule of (1); 3) transfecting or transforming a suitable host cell with the expression vector described in (2), and culturing in a host cell to express a protein; and (4) purifying the protein. Preparation can be carried out by techniques employed by those skilled in the art.
  • Another object of the present invention is to provide a method of treating cancer using the pharmaceutical composition of the present invention comprising administering to a patient or a subject an effective amount of the pharmaceutical composition.
  • the pharmaceutical composition is for treating a tumor or cancer associated with CD47 expression, including but not limited to acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non- Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, ovarian cancer, prostate cancer, lung cancer, colon cancer, breast cancer, pancreatic cancer and kidney cancer.
  • AML acute myeloid leukemia
  • CML chronic myeloid leukemia
  • ALL acute lymphoblastic leukemia
  • NHL non- Hodgkin's lymphoma
  • MM multiple myeloma
  • bladder cancer ovarian cancer, prostate cancer, lung cancer, colon cancer, breast cancer, pancreatic cancer and kidney cancer.
  • the CD47 associated disease is overexpressed, including but not limited to Crohn's disease, allergic asthma, rheumatoid arthritis.
  • the present invention provides a polynucleotide molecule encoding a recombinant bifunctional fusion protein, and an expression vector expressing the recombinant bifunctional fusion protein.
  • vectors include, but are not limited to, plasmids, viral vectors, yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), transformable artificial chromosomes (TAC), mammalian artificial chromosomes (MAC), and artificial additional chromosomes (HAEC).
  • the present invention provides a host cell comprising the above expression vector.
  • Host cells can be transformed or transfected with an expression vector.
  • Suitable host cells include E. coli, yeast and other eukaryotes.
  • E. coli, yeast or mammalian cell lines such as COS or CHO.
  • the expression vector used was pIg-Tail (R&D Systems). Extracellular membrane of SIRP ⁇ with primer 1 (SEQ ID No.: 9) and primer 2 (SEQ ID No.: 10), primer 1 (SEQ ID No.: 9) and primer 3 (SEQ ID No.: 11), respectively And the SIRP ⁇ D1 gene coding sequence from THP-1 ( The TIB-202 (TM ) cells were amplified and the PCR products were separately cloned into the HindIII/EcoRI site of the modified pIg-Tail vector to construct the pSIRP ⁇ -Fc and pSIRP ⁇ D1-Fc vectors.
  • the SIRP ⁇ D1 gene sequence carrying the N89A mutant was sent to Nanjing Kingsray Synthesis (item number: 7009323-1), and the synthesized gene was cloned into the HindIII/EcoRI site of the pIg-Tail vector to constitute a HY03M expression vector.
  • the Fc-terminal 192-site coding gene encoding the aspartic acid (GAC) of HY03M was mutated by site-directed mutagenesis PCR.
  • the alanine coding sequence (GCC) thereby obtaining the HY03MM expression vector.
  • DMEM fetal bovine serum
  • FBS fetal bovine serum
  • plasmid DNA and 2 ⁇ l of liposome 2000 were separately dissolved in 50 ⁇ l of serum-free medium, and the two were mixed together, allowed to stand at room temperature for 20 minutes, and then slowly added to the cell well. The cell culture plates were returned to the cell culture incubator for further 24 hours. The next day, 100 ⁇ l of supernatant was used to detect protein expression by enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • Protein expression assays were detected by ELISA.
  • the specific procedure is: the human antibody IgG-derived F(ab')2 fragment (Biosource International Inc) is dissolved in PBS phosphate buffer, and then added to a 96-well ELISA assay plate, 20 ng per well, and then the ELISA plate is placed. Overnight in a 4 degree refrigerator. For detection, block with blocking solution (PBS, 0.05% Tween 20, 3% fat-free milk) for one hour, then add the diluted supernatant, incubate for one hour at room temperature, and wash the solution (PBS, 0.05% Tween 20).
  • PBS blocking solution
  • HRP horseradish peroxidase
  • the transfected cells were subjected to a concentration-adjusted antibiotic pressure screening (Geneticin, Cat#10131035, Invitrogen), the unstable cells were gradually killed, and the remaining viable cells were diluted and added to five 96-well cell culture plates. Each well contains 0.5-1 cells.
  • the culture plate was placed in a cell culture incubator for 10-15 days, and then the cell well containing the single clone was detected by ELISA, and then the positively expressed cells were expanded and cultured, and serum-free Ex-CELL CD CHO medium was gradually used ( Cat#14361C-1000ML, SIGMA) domesticated culture. After further screening, the cell lines with the highest expression levels were selected and frozen for use.
  • the stably expressing cell strain (3 ⁇ 10 5 /ml) was inoculated into a 2 liter shake flask containing 300 ml of serum-free medium, and the shake flask was placed in a shaker and cultured until the cell density was grown to 5 ⁇ 10 6 /ml to harvest the culture supernatant. Purification was carried out using a Protein A column, and the purified protein was dialyzed into PBS (pH 7.0). Protein electrophoresis analysis ensures protein purity greater than 98%.
  • the binding activity of SIRP ⁇ -Fc, SIRP ⁇ D1-Fc, and HY03M to the target CD47 was measured by flow cytometry.
  • the binding activity to CD47 was detected by using two kinds of cell PC-3 cells and Jurkat cells, the former belonging to human prostate cancer cells and the latter being T lymphocyte leukemia cells. After washing the cells with PBS, the cells were suspended in PBS, adjusted to a cell concentration of 1 ⁇ 10 6 /ml, and hIgG (1 ⁇ g/ml) was added to the cell suspension, incubated in a refrigerator at 4 degrees for 1 hour, washed with PBS, and then transferred to 96 cells.
  • SIRP ⁇ -Fc (Cat#4546-SA-050, R&D Systems) protein (100 nM) with unlabeled, different concentrations, respectively.
  • SIRP ⁇ -Fc, SIRP ⁇ D1-Fc, HY03M, HY03MM and hIgG-Fc proteins were mixed together, then added to 96-well U-plate containing Jurkat cells, incubated in a 4 degree refrigerator for 1 hour, washed with PBS and resuspended in 200 ml PBS. The ratio of fluorescent positive cells at different concentrations was analyzed by flow cytometry.
  • the binding activity to different Fc ⁇ R proteins was detected by ELISA.
  • the specific method is as follows:
  • CD64 (Fc ⁇ RI) (Cat: 1257-FC-050 , R&D Systems), CD32a (Fc ⁇ RIIa) (Cat: 1330-CD- ) was coated with a coating buffer CBS (Sigma-Aldrich Co., Product code: 1001329288 C3041-100CAP).
  • Mouse macrophages (Raw264.7) were added to 96-well cell culture plates at 500,000 cells per well and cultured in a 37-degree incubator for 2 hours.
  • CFSE (2.25 uM)-labeled Jurkat cells were incubated with 2.5 ug/ml of HY03M, HY03MM, and IgG-Fc for 37 minutes, then transferred to a plate containing Raw264.7 cells and incubated at 37 degrees. Hours, washed three times with PBS, the free Jurkat cells were washed away, and then the CFSE signal in Raw264.7 cells was analyzed by flow cytometry.
  • the in vivo antitumor activity of HY03M was first studied using the HL60 subcutaneous tumor model. Twenty Balb/c nude mice were injected subcutaneously with leukemia (HL60) cells, and each mouse was injected with 4 ⁇ 10 6 cells. When the tumor grew to 100-150 mm 3 , it was randomly divided into three groups. The first group was intraperitoneally injected with PBS, and the second group. The group was intraperitoneally injected with VEGF inhibitor (VEGF inhibitor), and the third group was intraperitoneally injected with HY03M. The dose of each group was 10 mg/kg twice a week for 6 consecutive administrations. Tumor volume and body weight were measured twice a week.
  • VEGF inhibitor VEGF inhibitor
  • mice were injected subcutaneously with lymphoma (Daudi) cells, and each mouse was injected with 1 ⁇ 10 7 cells. When the tumor grew to 100-150 mm 3 , it was randomly divided into five groups. The first group was intraperitoneally injected with PBS.
  • the second group was intraperitoneally injected with HY03M
  • the third group was intraperitoneally injected with HY03MM
  • the fourth group was intraperitoneally injected with rituximab
  • the fifth group was intraperitoneally injected with HY03MM and rituximab.
  • the dose of each group was 5 mg/kg twice a week for 8 consecutive doses. Tumor volume and body weight were measured twice a week.
  • SIRP ⁇ D1-Fc The design structure of SIRP ⁇ D1-Fc is shown in Figure 1B and Figure 1D, and SIRP ⁇ D1 was ligated to the amino terminus of human IgG1-Fc by molecular cloning techniques.
  • the DNA and amino acid sequences of each protein are shown in Figure 2-5.
  • the gene coding sequence of SIRP ⁇ -Fc consists of 1752 nucleotides (Fig. 2A) (SEQ ID No.: 1), encoding a total of 583 amino acids (Fig. 2B) (SEQ ID No.: 2), of which 1047 cores
  • the nucleotides encode SIRP ⁇ , 696 nucleotides encode Fc, and 6 nucleotides are EcoRI digested into spots.
  • the gene coding sequence of SIRP ⁇ D1-Fc consists of 1131 nucleotides (Fig. 3A) (SEQ ID No.: 3), encoding a total of 376 amino acids (Fig. 3B) (SEQ ID No.: 4), 426 nucleotides
  • the code for SIRP ⁇ D1, 696 nucleotides encodes the Fc, and the 6 nucleotides are digested by EcoRI.
  • Both HY03M and HY03MM contain 1125 nucleotides, of which HY03M contains the N89A mutation (Fig. 4A, 4B) (SEQ ID No.: 5 & No.: 6), while HY03MM contains the N89A and D192A double mutation (Fig. 5A, 5B) (SEQ. ID No.: 7 & No.: 8).
  • the theoretical molecular weights of the four proteins are: SIRP ⁇ -Fc: ⁇ 128kDa, SIRP ⁇ D1-Fc: ⁇ 82.7kD, HY03M: ⁇ 82.3kDa, HY03MM: ⁇ 82.3kDa.
  • Protein electrophoresis (SDS-PAGE) analysis revealed that the protein molecular weight was greater than the theoretical molecular weight under non-reducing conditions (Fig. 6), which may be due to glycosylation of the protein because of an asparagine in the SIRP ⁇ D1 region. Linked glycosylation sites.
  • Irregular glycosylation at this site is likely to be responsible for the presence of two bands under the reducing conditions of SIRP ⁇ D1-Fc on SDS-PAGE gel (Fig. 6B) since removal of the glycosylation site (HY03M and HY03MM) The two bands become a band (Fig. 6C, 6D).
  • aspartic acid (D) at position 265 of the human IgG1-Fc region, which plays a key role in the function of the antibody. If the aspartate is mutated to alanine (D265A), the IgG is almost complete.
  • the binding activity to Fc ⁇ Rs (Fc ⁇ RI, Fc ⁇ RIIA, Fc ⁇ RIIB, Fc ⁇ RIIIA) was lost (Shields RL, et al., 2001) and the corresponding activities of ADCC, CDC and the like.
  • HL60 subcutaneous tumor model we first studied the in vivo antitumor activity of HY03M protein. As shown in Fig. 10A, tumor growth was not significantly inhibited in tumor-bearing mice treated with VEGF inhibitor, while HY03M treatment significantly inhibited tumor growth, and the tumor size gradually decreased from 100 mm 3 at the beginning of treatment to the experiment. It almost disappeared at the end. The tumor volume of the negative control mice gradually grew with time, and the tumor volume reached 1000 mm 3 at the end. The results of this experiment showed that inhibition of VEGF activity alone did not have a significant therapeutic effect on HL60 tumors, indicating that the growth of HL60 tumors was not strongly dependent on VEGF. However, blocking the inhibition function of macrophage phagocytic activity induced by tumor cells can enhance the phagocytosis of tumor cells by macrophages and thereby destroy tumor cells.
  • HY03M protein has strong anti-tumor activity, and for HL60 model, the efficacy of completely eliminating tumor can be achieved.
  • the main anti-tumor mechanism of this protein includes two aspects, on the one hand, by blocking the binding of CD47 to SIRP ⁇ , thereby blocking the inhibitory signal of SIRP ⁇ transmission and passively activating macrophages; on the other hand, by binding of Fc to Fc ⁇ Rs Actively activate macrophages.
  • Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly. J Cell Biol. 2003; 1179–1189.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)

Abstract

提供了一种重组融合蛋白，所述融合蛋白包含人信号调节蛋白alpha(SIRPα)的膜外端第一个Ig样区(SIRPαD1)和人IgG1的Fc片段。还提供了编码所述融合蛋白的多核苷酸、包含所述多核苷酸的表达载体、制备所述融合蛋白的方法以及治疗由过度表达CD47引起的疾病的方法。

Description

一种新的重组双功能融合蛋白及其制备和应用 技术领域
本发明涉及一种重组双功能融合蛋白及其制备方法和应用，尤其是其在肿瘤治疗中的应用。
背景技术
肿瘤细胞为了加速自身的生长，往往“发明”一些途径来逃避宿主对肿瘤细胞的免疫监视。已知的途径包括三种：1)逃避T淋巴细胞的免疫监视。肿瘤细胞往往高表达膜蛋白PD-L1及PD-L2，而PD-L1/PD-L2可以与T细胞膜表面的PD-1结合，诱导T细胞凋亡。2)逃避天然杀伤(NK)细胞的免疫监视。NK细胞的细胞膜上有一种能激活NK细胞的蛋白NKG2D，当NKG2D与肿瘤细胞膜上的MICA/MICB结合以后，可以激活NK细胞对肿瘤细胞的杀伤。但是肿瘤细胞本身则有一种机制可以促使MICA/MICB从细胞膜上脱落，脱落掉的MICA/MICB与NK细胞膜表面的NKG2D结合，从而封闭了NKG2D与肿瘤细胞膜表面的MICA/MICB结合。3)逃避巨噬细胞(Mφ)的免疫监视。几乎所有的肿瘤细胞在其细胞膜表面都高表达CD47，而CD47可与巨噬细胞(Mφ)膜表面的信号调节蛋白(SIRPα)结合，从而诱导一种抑制性信号，抑制巨噬细胞(Mφ)对肿瘤细胞的吞噬功能。所以肿瘤细胞很“聪明”，之所以能快速生长繁殖，是由于其“创造”的逃避机制所决定的。相应的，要想消灭肿瘤，就要从这些途径入手，并结合其它手段来设计有效的药物。
本发明则是针对信号调节蛋白SIRPα。信号调节蛋白(SIRP)是一种穿膜糖蛋白，包括三个家族成员，SIRPα(CD172a)、SIRPβ(CD172b)、SIRPγ(CD172g)。这三个成员具有相似的膜外端，但不同的膜内区(图1A)。膜外端均含有三个免疫球蛋白(Ig)样区域，其中第一个区域属于Ig-V区，第二、三个区域属于Ig-C区。SIRPα(CD172a)的膜内区含有两个抑制性信号域，可传递抑制信号，抑制细胞的相应功能。SIRPβ(CD172b)和SIRPγ(CD172g)膜内区很短，没有信号传递区域，但SIRPβ(CD172b)可通过适配器蛋白(Adaptor protein，如DAP12)传递激活信号(图1)。SIRPs蛋白主要表达在巨噬细胞(Mφ)、树突状细胞(DC)、及神经元细胞。
CD47也是一种穿膜糖蛋白，属于免疫球蛋白超家族成员，在包括红细胞在内的几乎所有细胞表面表达。CD47的配体包括黏附因子(integrins)、凝血酶敏感蛋白1(thrombospondin-1)、以及信号调节蛋白(SIRPs)。CD47具有多种生物学功能，包括细胞迁移、T细胞、树突状细胞活化、轴突发育等。除此之外，CD47通过与SIRPα相互作用可抑制巨噬细胞的吞噬作用。CD47以这种方式传递一种所谓的“不要吃我”("Don't eat me")信号，可以保护血细胞等正常细胞不被巨噬细胞吞噬。
研究发现，除正常组织细胞表达CD47以外，许多肿瘤细胞过度表达 CD47，并通过与巨噬细胞表面的SIRPα相结合而阻止巨噬细胞对肿瘤细胞的吞噬，这被视为肿瘤逃避机体免疫监视的一种机制。高表达CD47的肿瘤包括急性髓样白血病细胞(AML)、慢性髓样白血病细胞(CML)、急性淋巴细胞白血病细胞(ALL)、非何杰金氏淋巴瘤(NHL)、多发性骨髓瘤(MM)、膀胱癌、卵巢癌、前列腺癌、肺癌、大肠癌、乳腺癌、胰腺癌等等。
研究表明，用具有阻断CD47-SIRPα结合活性的CD47-特异性抗体给荷瘤小鼠注射，可以显著抑制肿瘤在小鼠体内的生长。给携带有人白血病细胞的小鼠注射同样的抗体则可以达到完全消灭肿瘤细胞的效应(Theocharides APA,et al.,2012)。
Fc受体是在某些细胞表面发现的蛋白质。所述细胞包括：B淋巴细胞、滤泡树突状细胞、自然杀伤细胞、巨噬细胞、中性粒细胞、嗜酸性细胞、嗜碱性细胞、肥大细胞这些有助于免疫系统的保护功能的细胞。Fc受体与附着在受感染细胞、侵入的病原体或癌细胞上的抗体结合，并刺激吞噬细胞或细胞毒性细胞，从而通过抗体介导的噬菌作用或抗体依赖细胞介导的细胞毒性作用来摧毁微生物、受感染细胞或癌细胞。
关于SIRPα-Fc及SIRPαD1-Fc与CD47的结合活性，以前曾有报道(Lee WY et al，2007)，但其与靶点CD47的亲和活性不足。
发明内容
本发明涉及一种基因重组融合蛋白，可以通过两种机制达到消灭肿瘤的目的，一是通过阻断肿瘤细胞诱导的巨噬细胞的抑制性信号，一是通过直接激活巨噬细胞的吞噬作用。该蛋白由人信号调节蛋白(Signal-regulatory proteins)alpha(SIRPα)的膜外端第一个Ig样区(SIRPαD1)与人IgG1的Fc片段连接而成(SIRPαD1-Fc)。该蛋白属于同源二聚体，分子量为90kDa由SIRPα的膜外端第一个区域(Domain1,D1)与人IgG的Fc片段所组成的融合蛋白(SIRPαD1-Fc)，与整个膜外端重组蛋白(SIRPα-Fc)相比，具有更高的靶点结合活性。本发明人进一步发现，去除SIRPα膜外端D1区域的糖基化位点(N89A)可进一步增加靶点的结合活性；而保留Fc与Fc受体的结合活性可以大大增加SIRPαD1-Fc的抗肿瘤活性。
经过细胞株筛选，利用中国仓鼠卵巢细胞(CHO)制备了该蛋白的稳定表达细胞株，并经过摇床培养制备了该蛋白。体外实验证实，该蛋白可与CD47结合，结合活性比SIRPα-Fc显著增加。而如果把SIRPαD1中的糖基化位点“NIT”通过基因修饰予以去除(N89A)(SIRPαD1-Fc(N89A),命名为HY03M)，则HY03M与靶点CD47的结合活性进一步增强。而如果把Fc区域的第192个氨基酸从天冬氨酸突变为丙氨酸(D192A)(SIRPαD1-Fc(N89A/D192A)，命名为HY03MM)，则HY03MM与Fc受体(CD16a、CD32、CD64)的结合活性显著降低。利用人急性淋巴细胞白血病及急性早幼粒细胞白血病小鼠模型，研究了HY03M的体内抗肿瘤疗效，结果表明，HY03M具有强大的抗肿瘤活性，经过HY03M治疗的小鼠，肿瘤细胞的生长被完全抑制，个别小鼠已检测不到肿瘤。为验证HY03M的Fc是否参与抗肿瘤活性，在人淋巴瘤小鼠模型中比较研究了HY03M及HY03MM的体内 疗效，并与美罗华进行了比较。结果发现，与阴性对照组相比，HY03M具有显著的抗肿瘤疗效，其疗效显著优于美罗华。而HY03MM虽然具有明显的肿瘤生长抑制活性，但与HY03M相比，其活性大大降低，提示Fc区域通过与巨噬细胞的Fc受体结合，参与了抗肿瘤活性。
在一个实施例中，本发明的重组蛋白为HY03M(SEQ ID NO.:5、SEQ ID NO.:6)。HY03M具有强大的抗肿瘤活性，其作用原理包括两个方面：1)通过阻断CD47-SIRPa的相互作用；2)通过Fc与Fc受体的结合激活巨噬细胞；HY03M可用于治疗各种靶点阳性的肿瘤。
本发明还提供了一种编码重组双功能融合蛋白的核酸分子、一种表达所述蛋白的表达载体、一种制备改蛋白的方法以及一种治疗过度表达CD47的疾病的方法。
在一个实施例中，本发明的重组双功能融合蛋白包括信号调节蛋白(SIRP)膜外端的Ig样区，与人IgG1的Fc片段连接，其中所述蛋白与CD47结合，从而阻断CD47与巨噬细胞表面SIRP的结合，激活巨噬细胞对肿瘤细胞的吞噬。
在一个实施例中，重组双功能融合蛋白中的所述信号调节蛋白为SIRPα，信号调节蛋白膜外端的Ig样区为SIRPαD1。
在一个实施例中，本发明的重组双功能融合蛋白包括Fc片段，其为免疫球蛋白分子的一部分。虽然Fc片段没有抗原结合位，但其有助于一些效应子功能，例如在多种细胞上帮助抗体与Fc受体的结合以及与补体系统的结合。在一个实施例中，Fc片段为IgG1的Fc片段。
在一个实施例中，本发明的重组双功能融合蛋白包括与SEQ ID NO.:6具有至少95％相似性的氨基酸序列。在一个实施例中，本发明的重组双功能融合蛋白的氨基酸序列与SEQ ID NO.:6具有至少98％的相似性。在一个实施例中，本发明的重组双功能融合蛋白的氨基酸序列与SEQ ID NO.:6具有至少99％的相似性。在一个实施例中，本发明的重组双功能融合蛋白包括SEQ ID NO.:6的氨基酸序列。
在一个实施例中，本发明提供一种编码本发明的重组双功能融合蛋白的多聚核苷酸分子，其包括信号调节蛋白(SIRP)膜外端的Ig样区，与人IgG1的Fc片段连接，其中所述蛋白与CD47结合，从而阻断CD47与巨噬细胞表面SIRP的结合，激活巨噬细胞对肿瘤细胞的吞噬。
在一个实施例中，本发明的多聚核苷酸分子编码重组双功能融合蛋白，其包括SIRPα，优选SIRPαD1。
在一个实施例中，本发明的多聚核苷酸分子编码重组双功能融合蛋白，其包括Ig的Fc片段，优选人IgG1的Fc片段。
在一个实施例中，本发明的多聚核苷酸分子编码重组双功能融合蛋白，其包括与SEQ ID NO.:6具有至少95％相似性的氨基酸序列。在一个实施例中，本发明的重组双功能融合蛋白的氨基酸序列与SEQ ID NO.:6具有至少98％的相似性。在一个实施例中，本发明的重组双功能融合蛋白的氨基酸序列与SEQ ID NO.:6具有至少99％的相似性。在一个实施例中，本发明的多聚核苷酸分子编码重组双功能融合蛋白，其包括SEQ ID NO.:6的氨基酸序列。
在一个实施例中，本发明提供一种包括本发明的多聚核苷酸分子的表达载体， 所述多聚核苷酸分子编码重组双功能融合蛋白。
在一个实施例中，本发明提供一种包括本发明的表达载体的宿主细胞。
在一个实施例中，本发明提供一种药物组合物，包括本发明的重组双功能融合蛋白以及至少一种佐剂。
在一个实施例中，本发明提供一种治疗由过度表达CD47引起的疾病的方法，包括向病人或对象给予治疗有效量的本发明的药物组合物。在一个实施例中，本发明提供一种重组双功能融合蛋白在制备用于治疗CD47过度表达引起的疾病。
在一个实施例中，本发明的方法用于治疗的疾病选自髓细胞性白血病(AML)、慢性粒细胞白血病(CML)、急性淋巴细胞白血病(ALL)、非霍奇金淋巴瘤(NHL)、多发性骨髓瘤(MM)、膀胱癌、卵巢癌、前列腺癌、肺癌、结肠癌、乳腺癌、胰腺癌以及肾细胞癌。在一个实施例中，本发明提供一种用于治疗克罗恩病、髓过敏性哮喘以及类风湿性关节炎。
附图说明
图1是SIRPs和SIRPαD1-Fc的分子结构及工作示意图。
图2是SIRPα-Fc核苷酸及氨基酸序列。
图3是SIRPαD1-Fc核苷酸及氨基酸序列。
图4是HY03M核苷酸及氨基酸序列。
图5是HY03MM核苷酸及氨基酸序列。
图6是四种融合蛋白的SDS-PAGE电泳图。
图7是SIRPα-Fc与SIRPαD1-Fc与PC-3细胞靶点结合活性分析结果。
图8是未标记蛋白对荧光标记SIRPα-Fc的靶点阻断活性分析。
图9是Fc受体结合活性及诱导巨噬细胞对肿瘤细胞的吞噬活性。
图10是四种融合蛋白对肿瘤的体内药效。
具体实施方式
本发明涉及一种基因重组融合蛋白，可以通过两种机制达到消灭肿瘤的目的，一是通过阻断肿瘤细胞诱导的巨噬细胞的抑制性信号，一是通过直接激活巨噬细胞的吞噬作用。该蛋白由人信号调节蛋白(Signal-regulatory proteins)alpha(SIRPα)的膜外端第一个Ig样区(SIRPαD1)与人IgG1的Fc片段连接而成(SIRPαD1-Fc)。该蛋白属于同源二聚体，分子量为90kDa。经过细胞株筛选，我们利用中国仓鼠卵巢细胞(CHO)制备了该蛋白的稳定表达细胞株，并经过摇床培养制备了100毫克该蛋白。体外实验证实，该蛋白可与CD47结合，结合活性比SIRPα-Fc显著增加。而如果把SIRPαD1中的糖基化位点“NIT”通过基因修饰予以去除(N89A)(SIRPαD1-Fc(N89A),命名为HY03M)，则HY03M与靶点CD47的结合活性进一步增强。而如果把“Fc区域的第211个氨基酸从天冬氨酸突变为丙氨酸(D192A)(SIRPαD1-Fc(N89A/D192A)，命名为HY03MM)，则HY03MM与Fc受体(CD16a、CD32、CD64)的结合活性显著降低。利用人急性淋巴细胞白血病及急性早幼粒细胞白血病小鼠模型，我们研 究了HY03M的体内抗肿瘤疗效，结果表明，HY03M具有强大的抗肿瘤活性，经过HY03M治疗的小鼠，肿瘤细胞的生长被完全抑制，个别小鼠已检测不到肿瘤。为验证HY03M的Fc是否参与抗肿瘤活性，我们在人淋巴瘤小鼠模型中比较研究了HY03M及HY03MM的体内疗效，并与美罗华进行了比较。结果发现，与阴性对照组相比，HY03M具有显著的抗肿瘤疗效，其疗效显著优于美罗华。而HY03MM虽然具有明显的肿瘤生长抑制活性，但与HY03M相比，其活性大大降低，提示Fc区域通过与巨噬细胞的Fc受体结合，参与了抗肿瘤活性。
本发明的融合蛋白包括两部分，即目标结合片段(即SIRPαD1)以及Fc片段。
本发明的重组双功能融合蛋白还可与非多肽分子结合以获得期望的性能，例如减少降解和/或提高半衰期(half-life)、减少毒性、降低免疫原性和/或提高生物活性。所述分子的例子包括但不限于：聚合物，如聚乙二醇(PEG)，多聚赖氨酸，葡聚糖；血脂；胆固醇组(如激素)；碳水化合物，或寡糖分子。
Fc片段的长度可以为232个氨基酸，包括铰链区(hinge region)中的一个半胱氨酸、CH2区中的两个半胱氨酸以及CH3区中的两个半胱氨酸。铰链区中的半胱氨酸用于形成两个单体间的二硫键，从而产生二聚体，CH2区及CH3区中的胱氨酸可以形成键内二硫键从而稳定所述蛋白。
例如，在融合蛋白中可使用能够与CD47结合的SIPR(SIRPα,SIRPγ)膜外端的Ig区。
较佳地，人源性序列可用于人类癌症的治疗，因为源于非人类动物的蛋白或肽具有强免疫原性，会导致过敏及其他副作用。然而，其他动物蛋白或肽可用于本发明的其他应用目的。
在一个实施例中，本发明的重组双功能融合蛋白中的所述信号调节蛋白为SIRPα。所述信号调节蛋白膜外端的Ig样区为SIRPαD1.
本发明可以使用任何免疫球蛋白的Fc片段。免疫球蛋白包括IgG,IgA,IgM,IgD以及IgA，其中IgG最丰富以及相对稳定的。优选IgG的Fc片段、IgG1的Fc片段、人IgG1的Fc片段，因为该些Fc片段显示出对葡萄球菌蛋白A(staphylococcus Protein A)具有最高的结合性，从而容易被纯化。
在一个实施例中，本发明的重组双功能融合蛋白包括人SIRPα膜外端的第一Ig样区，通过人IgG1的Fc片段连接。
在一个实施例中本发明的重组双功能融合蛋白的氨基酸序列如图4B(SEQ ID NO.:6)。在另一个实施例中，所述重组双功能融合蛋白包括SEQ ID NO.:6所示序列的多肽。在另一个实施例中，所述多肽的氨基酸序列与SEQ ID NO.:6具有至少80％、85％、90％、95％、98％或99％的相似性，其中所述多肽能够与CD47结合，并能抑制肿瘤细胞的生长。
本发明另一方面提供了一种分离的核酸分子，包括编码重组双功能融合蛋白的多聚核苷酸，所述蛋白包括SEQ ID NO.:6所示序列的多肽。在一个实施例中，所述多肽的氨基酸序列与SEQ ID NO.:6具有至少80％、85％、90％、 95％、98％或99％的相似性，其中所述多肽能够与CD47结合，并能抑制肿瘤细胞的生长。
本发明还提供一种药物组合物，包括前述重组双功能融合蛋白以及至少一种药学上接受的赋形剂。根据需要，所述药物组合物中还可包括一种或多种载体或赋形剂。所述载体包括药剂学中常见的稀释剂、赋形剂、膨胀剂、黏结剂、润湿剂、崩解剂、吸收促进剂、表面活性剂、吸附载体、润滑剂等。
所述组合物包括治疗或与预防上有效量多肽或蛋白，并混合有药学上可接受的物质及生理学上可接受的制剂物质。所述药物组合物可包括用于修改、维持或保藏的制剂物质，例如，pH值，渗透压，粘度，透明度，颜色，气味，无菌，保序性，稳定性，溶解或释放率，组合物的吸附和渗透。合适的配方的材料包括，但不限于，氨基酸(如甘氨酸，谷氨酰胺，天冬酰胺，精氨酸和赖氨酸)；抗菌药物；抗氧化剂(如抗坏血酸，亚硫酸钠或亚硫酸氢钠)；缓冲剂(如硼酸，碳酸氢铵，Tris-HCl，柠檬酸盐，磷酸盐，其他有机酸)；膨胀剂(如甘露醇、甘氨酸)，螯合剂(如乙二胺四乙酸(EDTA))；络合剂(如咖啡因，聚乙烯吡咯烷酮，β-环糊精或羟丙基-β-环糊精)；填料；单糖；二糖和其他碳水化合物(如葡萄糖，甘露糖，或糊精)；蛋白质(如血清白蛋白，明胶或免疫球蛋白)；着色；调味品和稀释剂；乳化剂；亲水性聚合物(如聚乙烯吡咯烷酮)；低分子量多肽；成盐的抗衡离子(如钠)；防腐剂(如苯扎氯铵，苯甲酸，水杨酸，硫柳汞，苯乙醇，对羟基苯甲酸甲酯，尼泊金丙酯，洗必泰，山梨酸或过氧化氢)；溶剂(如甘油，丙二醇或聚乙二醇)；糖醇(如甘露醇或山梨醇)；悬浮剂；表面活性剂或润湿剂(如PLURONICS，PEG，山梨酸酯，聚山梨酯类如聚山梨酯20，聚山梨酯80，Triton，氨丁三醇，卵磷脂，胆固醇，tyloxapal)；稳定性增强剂(蔗糖和山梨醇)；紧张性增强剂(如碱金属卤化物，最好是氯化钠和氯化钾，甘露醇山梨醇)；输送剂；稀释剂；赋形剂和/或药用辅料。
本领域技术人员会根据计划的给予途径、输送形式以及期望的剂量选择理想的药物组合物。例如，请参见Remington's Pharmaceutical Sciences,supra。该些药物组合物会影响物理状态、稳定性、多肽的体内释放率以及体内清除率。例如，适当的组合物可以为注射用水、生理盐水。
在药物组合物中的主要载体可以是水性或非水性。例如，一个合适的载体可以是注射用水，生理盐水或人工脑脊液，可辅以其他常见的注射用材料。例如，载体可是是中性缓冲溶液或生理盐水与血清白蛋白混合。另一个典型的药物组合物包含Tris缓冲液，或醋酸缓冲液，其可进一步包括山梨醇或合适的替代物。在本发明的一个实施例中，为了便于存储，组合物可以通过将具有期望纯度的所选组合物与可选的制剂混合(Remington's Pharmaceutical Sciences,supra)，以冻干蛋糕或水溶液形式来制备。此外，治疗组合物可使用适当的辅料，如蔗糖配制成冻干物。
所述制剂可以各种方法输送，例如，通过吸入治疗，口服或注射。当考虑胃肠外给药时，本发明的药物组合物的形式可以是胃肠外可接受的水溶液，其 包括药学上可接受载体中所需的多肽。一种特别适合胃肠外注射载体为无菌蒸馏水，其中多肽以适合保存的无菌、等渗溶液形式制备。另一种制备包含所需的分子与一种制剂，如注射微球，生物性微粒，聚合物(聚乳酸，聚乙醇酸)，珠，或脂质体，其用于产品的缓释及持续释放，随后通过积存注射(depot injection)输送。也可以使用透明质酸，这会促进血液循环中的缓释持续时间。期望分子引入的其他合适的手段包括可植入的药物输送装置。
在另一方面，适用于注射给药的药物制剂可以水溶液形式制备，最好是在生理学上可相容的缓冲剂，如汉克斯液(Hanks'solution)，林格液(Ringer's solution)，或生理缓冲液。注射水悬浮液可含有增加悬浮液粘度的物质，如羧甲基纤维素钠，山梨糖醇，或葡聚糖。此外，该活性化合物悬浮液可制备成适当的油性注射悬浮液。合适的脂溶性溶剂或载体包括脂肪油，如香油，或合成脂肪酸酯，如油酸乙酯，甘油三酯，或脂质体。非脂质的阳离子氨基聚合物也可用于输送。可选地，悬浮液还可含有合适的稳定剂或制剂，以增加化合物的水溶性并允许高浓度溶液的制备。在另一实施例中，一种药物组合物可被配制用于吸入。吸入溶液也可以以推进剂的形式制备，用于气溶胶输送。在另一实施例中，溶液可以是雾化的。肺部的给予在PCT申请号为PCT/US94/001875中进一步描述，它描述了化学修饰的蛋白的肺部给药。
可以想到某些制剂可以以口服的形式给予。在本发明的一个实施例中，以这种方式给药的分子可以用固体剂型如片剂和胶囊中常用的载体来制备，也可不包含所述载体。例如，当需要最大化生物利用度并最小化预系统降解时，胶囊可被设计用于在胃肠道中释放活性物质。可包括附加剂，从而促进治疗分子的吸收。还可使用稀释剂，香料，低熔点蜡，植物油，润滑油，悬浮剂，片剂的崩解剂和粘结剂。口服药物组合物可以用本领域熟悉的药学上可接受的、适于口服的载体制备。这样的载体可使药物组合物以片剂，丸剂，粒糖衣丸，胶囊，液体，凝胶，糖浆，浆，悬浮液等的形式被病人服用。
口服制剂可以通过将活性化合物与固体赋形剂结合，并加工颗粒的混合物来得到(可选，研磨后)，从而获得片剂或糖衣丸芯。可以添加适当的助剂，如果需要的话。适宜的赋形剂包括碳水化合物或蛋白质的填料，如糖，包括乳糖，蔗糖，甘露醇，山梨醇；玉米，小麦，大米，土豆淀粉，或其他植物；纤维素，如甲基纤维素，羟丙基甲基纤维素，或羧甲基纤维素钠；黏胶，包括阿拉伯胶浆；和蛋白质，如明胶及胶原。如果需要的话，可增加崩解或溶解剂，如交联聚乙烯吡咯烷酮，琼脂，和藻酸或其盐，如褐藻酸钠。
糖衣丸芯可与适当的涂层的结合，如浓缩糖溶液，其中还可以包含阿拉伯胶，滑石，聚乙烯吡咯烷酮，卡波姆凝胶，聚乙二醇，和/或二氧化钛，漆溶剂，和合适的有机溶剂或溶剂混合物。可向片剂或糖衣丸芯添加染料或颜料，用于产品识别或区分活性化合物的数量即剂量。
口服药物制剂还包括明胶制成软、封闭的推入配合胶囊，以及涂层，如甘油或山梨醇。推入配合胶囊含有活性成分，与填料和粘合剂混合，如乳糖和淀粉，润滑剂，如滑石粉、硬脂酸镁，以及任选的稳定剂。在软胶囊中，活性化 合物可以溶解或悬浮在合适的液体，如脂肪油，液，或液体聚乙二醇，可添加也可不添加稳定剂。
对于本领域技术人员容易理解可包含额外的药物组合物，包括用于缓释及持续释放配方的多肽。本领域的技术人员也熟知各种其他缓释及持续释放配方的手段，如脂质体载体，生物性微粒或多孔珠和长效注射剂。例如，PCT/US93/00829描述了用于控制药物组合物输送的多孔聚合物微粒释放。缓释制剂另外的例子包括在物品的形状，微粒形式的半透膜聚合物矩阵，例如薄膜或微胶囊。缓释矩阵可以包括聚酯，水凝胶，聚乳酸(Langer et al.,J.Biomed.Mater.Res.,15:167-277,(1981)；Langer et al.,Chem.Tech.,12:98-105(1982)),ethylene vinyl acetate(Langer et al.,supra)or poly-D(-)-3-hydroxybutyric acid(EP 133,988)，乙烯醋酸乙烯酯(Langer et al.,supra)或聚-D(-)-3-羟基丁酸(EP 133,988)。缓释组合物还包括脂质体，其可通过本领域已知的几种方法制备。例如，参见Eppstein et al.,PNAS(USA),82:3688(1985)；EP 36,676；EP 88,046；EP 143,949。
用于体内给予的所述药物组合物通常必须是无菌的。这可以通过无菌过滤膜过滤来实现。当组合物为冻干时，这种方法可以在灭菌或冻干重组之前或之后进行。胃肠外给药的组合物可以以冻干形式或溶液的形式储存。此外，肠外用组合物通常是放置到具有无菌接入口的容器中，例如具有塞子的静脉输液袋或瓶，所述塞子通过皮下注射针可被刺穿。
一旦药物组合物被制备，它可以以溶液，悬浮液，凝胶，乳液，固体，或脱水或冻干粉的形式被存储在无菌瓶内。这样的制剂可以以给药前待用的形式或需要重建(例如，冻干)的形式存储。
在一个具体实施例中，本发明涉及用于制备单剂量给药单元的试剂盒。所述试剂盒可以包含具有干燥蛋白的第一容器以及具有水性制剂的第二容器。本发明还包含单、多腔预填充注射器(例如，液体注射器和lyosyringes)。
药物组合物用于治疗的有效量取决于，例如，治疗环境及对象。本领域技术人员能够理解，用于治疗的适当剂量水平部分区别于分子的输送，多肽使用的指标，给药途径，和病人的尺寸(体重，体表或器官大小)和条件(年龄和一般健康)。因此，临床医生可滴定剂量并修改给药途径从而获得最佳的治疗效果。一个典型的剂量范围为约0.1毫克/公斤至100毫克/公斤或更多，这取决于上述因素。多肽组合物可优选注射或静脉注射。长效药物组合物可以根据半衰期和具体配方的清除率每三到四天，每一周或两周给予。给药频率取决于所使用的制剂的多肽药物动力学参数。通常，给予组合物直到用量达到预期的效果。因此，该组合物可随着时间的推移作为单剂量或多剂量(以相同的或不同的浓度/剂量)或作为持续注射给予。可进一步调节适当的剂量。适当的剂量可通过使用适当的剂量-反应数据确定。
药物组合物的给药途径是已知的，如口服，通过静脉，腹腔内，脑(脑实质)，侧脑室，肌肉，内眼动脉，门静脉，病灶内路线，髓内，鞘内注射，脑室，透皮，皮下，或腹腔内注射；以及鼻内，肠内，外用，舌下，尿道，阴道，或直肠的手段，通过缓释系统或通过植入装置。如需要，所述组合物可以通过 单次快速静脉注射或连续输注给药，或通过注入装置注射。可替换地或附加地，该组合物可局部给药，通过膜，海绵植入，或其他合适的材料上吸附或包裹所需的分子来给药。如使用植入装置，该装置可以移植到任何合适的组织或器官，并可以通过扩散，定时释放丸，或连续给药的方式输送预期的分子。
在某些情况下，本发明的重组双功能融合蛋白可以通过移植某些细胞输送，所述细胞通过于此描述的方法被转基因，从而表达和分泌多肽。这些细胞可能是动物或人类的细胞，可以示自体，异体或异种的。可选地，可以是永生化的细胞。为了降低免疫反应的机会，封闭这些细胞以避免周围组织浸润。封闭材料通常是生物相容性的，半渗透性的聚合物外壳或膜，其允许释放多肽产物，但可通过病人的免疫系统或周围组织的其他破坏因素来防止破坏细胞。
还可进行体内基因治疗，其中向对象直接引入编码本发明重组双功能融合蛋白的核酸分子，或其衍生物。例如，一个核酸编码一个双功能融合蛋白，通过核酸的局部注射向靶细胞引入编码本发明的重组双功能融合蛋白的核酸序列，可选使用输送载体，如腺相关病毒载体。替代病毒载体包括但不限于，逆转录病毒，腺病毒，单纯疱疹病毒和乳头瘤病毒载体。该病毒载体的体内通物理输送可通过局部注射所需的核酸构建体或其他适当含有目标核酸序列的输送载体，脂质体介导转移，直接喷射(裸DNA)，或微粒轰击(基因枪)来实现。
本发明的组合物可以单独使用或与其它治疗剂的组合，来提高疗效或减少潜在的副作用。
本发明的另一目的是提供一种方法，用于制备所述重组双功能融合蛋白和包含它的药物组合物。在一个实施例中，所述方法包括：(1)提供一种用于编码的多聚核苷酸分子；(2)构建含有(1)中所述多聚核苷酸分子的表达载体；(3)用(2)中所述表达载体转染或转化合适的宿主细胞，并在宿主细胞中培养，以表达蛋白；以及(4)纯化所述蛋白。制备可通过本领域技术人员供职的技术进行。
本发明的另一目的是提供一种使用本发明药物组合物治疗癌症的方法，包括向病人或对象给予有效量的所述药物组合物。在一个实施例中，所述药物组合物用于治疗CD47表达相关肿瘤或癌症，包括但不限于急性髓系白血病(AML)，慢性粒细胞白血病(CML)，急性淋巴细胞白血病(ALL)，非霍奇金淋巴瘤(NHL)，多发性骨髓瘤(MM)，膀胱癌，卵巢癌，前列腺癌，肺癌，结肠癌，乳腺癌，胰腺癌和肾癌。
在一个实施例中，过度表达CD47相关疾病，包括但不限于克罗恩病，过敏性哮喘，类风湿性关节炎。
同时，本发明提供了一种编码重组双功能融合蛋白的多聚核苷酸分子，以及一种表达所述重组双功能融合蛋白的表达载体。所述载体的例子包括但不限于质粒，病毒载体，酵母人工染色体(YAC)，细菌人工染色体(BAC)，可转化人工染色体(TAC)，哺乳动物人工染色体(MAC)和人工附加染色体(HAEC)。
本发明提供包括上述表达载体的宿主细胞。宿主细胞可用表达载体转化或转染。合适的宿主细胞包括大肠杆菌，酵母菌和其它真核生物。优选地，大肠杆菌，酵母或哺乳动物细胞系(如COS or CHO)的使用。
本发明将通过非限制性的例子进一步被详细描述。
实施例
实施例1：
实验材料及方法
1.1、SIRPα-Fc及SIRPαD1-Fc表达载体构建
表达载体用的是pIg-Tail(R&D Systems)。用引物1(SEQ ID No.:9)和引物2(SEQ ID No.:10)、引物1(SEQ ID No.:9)和引物3(SEQ ID No.:11)分别将SIRPα的膜外端及SIRPαD1基因编码序列从THP-1(
Figure PCTCN2015094739-appb-000001
TIB-202TM)细胞中扩增出来，PCR产物分别克隆至改良过的pIg-Tail载体的HindIII/EcoRI位点，从而构成pSIRPα-Fc及pSIRPαD1-Fc载体。
1.2、HY03M及HY03MM表达载体的构建
将携带有N89A突变体的SIRPαD1基因序列送交南京金斯瑞合成(项目编号：7009323-1)，合成的基因克隆至pIg-Tail载体的HindIII/EcoRI位点，从而构成HY03M表达载体。利用引物4(SEQ ID No.:12)和引物5(SEQ ID No.:13)，经定点突变PCR，将HY03M的Fc端192位点编码天冬氨酸的基因序列(GAC)突变成丙氨酸编码序列(GCC)，由此得到HY03MM表达载体。
表1、PCR引物
Figure PCTCN2015094739-appb-000002
注解:斜体代表基因特异性序列，下划线代表内切酶识别序列。
2、蛋白表达及纯化
将含有CHO细胞的完全培养基(DMEM，10％FBS)加入到24-孔培养板中，每孔0.5ml，将培养板放置在细胞培养箱中培养24小时。转染时，将
0.5μg质粒DNA及2μl脂质体2000(Cat#11668-027,Invitrogen)分别溶解到50μl无血清培养基中，将二者混到一起，室温放置20分钟，然后缓缓加入到细胞孔中，并将细胞培养板放回到细胞培养箱中继续培养24小时。第二天取100μl上清用酶联免疫吸附检测法(ELISA)检测蛋白表达情况。
3、蛋白表达检测
蛋白表达检测是用ELISA检测的。具体步骤是：将针对人IgG的羊抗体F(ab’)2片段(Biosource International Inc)溶解到PBS磷酸缓冲液中，然后加入到96孔ELISA检测板中，每孔20ng,然后将ELISA板放置于4度冰箱过夜。检测时，用封闭液(PBS,0.05％吐温20，3％无脂牛奶)先封闭一小时，然后加入经过稀释的上清，室温孵育一个小时，经洗涤液(PBS,0.05％吐温20)洗涤5次，然后加入辣根过氧化物酶(HRP)标记的、针对人IgG Fc片段的兔抗体(Jackson ImmunoResearch Lab),室温孵育一个小时，洗涤5次后加入HRP的底物，显色反应2分钟后加入终止液(1N H2SO4)中止反应，用450nM波长测光密度。
4、稳定细胞株筛选
基因转染的细胞经过浓度递增的抗生素加压筛选(Geneticin,Cat#10131035,Invitrogen),不稳定的细胞将逐渐被杀死，剩余的存活细胞经过稀释加入到5个96孔细胞培养板中，每孔含有0.5-1个细胞。将培养板放置于细胞培养箱中培养10-15天，然后用ELISA对含有单个克隆的细胞孔进行检测，然后将阳性表达的细胞放大培养，并逐渐用无血清Ex-CELL CD CHO培养基(Cat#14361C-1000ML,SIGMA)驯化培养。经过进一步筛选，将具有最高表达水平的细胞株挑选出来冻存备用。
5、蛋白生产及纯化
将稳定表达细胞株(3x105/ml)接种到含有300ml无血清培养基的2升摇瓶中，将摇瓶放置于摇床中培养，待细胞密度生长至5x106/ml收获培养上清，用Protein A柱进行纯化，纯化后的蛋白经过透析置换到PBS中(pH7.0)。经过蛋白电泳分析，确保蛋白纯度大于98％。
6、靶点结合活性：
用流式细胞仪，分别测定SIRPα-Fc、SIRPαD1-Fc、HY03M与靶点CD47的结合活性。
与CD47的结合活性检测分别采用两种细胞PC-3细胞及Jurkat细胞，前者属于人前列腺癌细胞，后者为T淋巴细胞白血病细胞。细胞经PBS洗涤以后，悬浮于PBS中，调细胞浓度至1x106/ml，将hIgG(1μg/ml)加入到细胞悬液， 4度冰箱孵育1个小时，用PBS洗涤后将细胞转入96-孔U-型细胞培养板(Cat#163320，NUNC)中，每孔100μl，然后加入不同浓度的纯化蛋白，4度冰箱孵育1个小时，洗涤后悬浮于PBS，再与FITC标记的抗人IgG-Fc抗体(Cat#F9512，Sigma)进行孵育，一个小时后用流式细胞仪(Guava easyCyte 6HT-2L，Millipore)进行分析检测。
7、靶点阻断实验
为检测各纯化蛋白对CD47-SIRPα的结合是否具有阻断作用,我们利用FITC标记的SIRPα-Fc(Cat#4546-SA-050,R&D Systems)蛋白(100nM)分别与未标记的、不同浓度的SIRPα-Fc、SIRPαD1-Fc、HY03M、HY03MM及hIgG-Fc蛋白一起混合，然后加入到含有Jurkat细胞的96孔U-型板中，4度冰箱孵育1小时，经PBS洗涤后重悬于200mlPBS中，并用流式细胞仪分析不同浓度条件下荧光阳性细胞比率。
8、FcγR结合实验
与不同FcγR蛋白的结合活性采用ELISA方法进行检测。具体方法如下：
用包被缓冲液CBS(Sigma-Aldrich Co.,Product code:1001329288 C3041-100CAP)将CD64(FcγRI)(Cat:1257-FC-050,R&D Systems)、CD32a(FcγRIIa)(Cat:1330-CD-050/CF,R&D Systems)、CD32b(FcγRIIb)(Cat:1875-CD-050,R&D Systems)、CD16a(FcγRIIIa)(Cat:4325-FC-050,R&D Systems)稀释至1000ng/ml，取100ul加入到ELISA板(Cat#442404,NuncTM)中，每孔100ng,将包被板置于4℃冰箱过夜。检测时先用0.05％PBS-T洗涤包被板一次，再用3％脱脂牛奶室温封闭1小时。将稀释好的HY03M及HY03MM蛋白(800、400、200nM)加入到包被板中，每孔100ul。室温孵育一个小时以后，弃样品，用0.05％PBS-T洗涤5次，然后加入100ul经过稀释(1:20000)的HRP-Rabbit Anti-Human IgG Fc(Cat#:309-036-008,Jackson ImmunoResearch Lab)，室温孵育一个小时，洗涤液洗涤5次，加入HRP底物，避光显色10-20分钟以后用1N H2S04终止显色反应，于酶标仪上读取OD450值。
9、巨噬细胞吞噬实验
将小鼠巨噬细胞(Raw264.7)加入到96-孔细胞培养板中，每孔50万个细胞，37度培养箱培养2个小时。将CFSE(2.25uM)标记的Jurkat细胞与2.5ug/ml的HY03M、HY03MM、及IgG-Fc一起37度孵育30分钟，然后转入到含有Raw264.7细胞的培养板中，37度继续孵育3小时，经PBS洗涤三次，将游离的Jurkat细胞洗去，然后用流式细胞仪分析Raw264.7细胞内的CFSE信号。
10、抗肿瘤实验
利用HL60皮下肿瘤模型，首先对HY03M的体内抗肿瘤活性进行了研究。给20只Balb/c裸鼠皮下注射白血病(HL60)细胞，每只小鼠注射4x106个细 胞，待肿瘤生长至100-150mm3时随机分为三组，第一组腹腔注射PBS，第二组腹腔注射VEGF阻断剂(VEGF inhibitor)，第三组腹腔注射HY03M，每组药物剂量均为10mg/kg，每周两次，连续6次给药。每周两次测量肿瘤体积及体重。
为分析Fc端是否参与抗肿瘤活性，我们利用淋巴瘤模型分析了HY03M及HY03MM的抗肿瘤活性，并与美罗华(Rituximab)进行比较。给38只Balb/c裸鼠皮下注射淋巴瘤(Daudi)细胞，每只小鼠注射1x107个细胞，待肿瘤生长至100-150mm3时随机分为五组，第一组腹腔注射PBS，第二组腹腔注射HY03M，第三组腹腔注射HY03MM，第四组腹腔注射美罗华，第五组腹腔注射HY03MM及美罗华，每组药物剂量均为5mg/kg，每周两次，连续8次给药。每周两次测量肿瘤体积及体重。
实验结果
1、表达载体构建
SIRPαD1-Fc的设计结构如图1B和图1D所示，将SIRPαD1通过分子克隆技术连接在人IgG1-Fc的氨基端。各蛋白的DNA及氨基酸序列见图2-5。其中SIRPα-Fc的基因编码序列由1752个核苷酸组成(图2A)(SEQ ID No.:1)，共编码583个氨基酸(图2B)(SEQ ID No.:2)，其中1047个核苷酸编码SIRPα，696个核苷酸编码Fc，6个核苷酸为EcoRI酶切为点。SIRPαD1-Fc的基因编码序列由1131个核苷酸组成(图3A)(SEQ ID No.:3)，共编码376个氨基酸(图3B)(SEQ ID No.:4)，426个核苷酸编码SIRPαD1，696个核苷酸编码Fc，6个核苷酸为EcoRI酶切为点。HY03M及HY03MM均含有1125个核苷酸，其中HY03M含有N89A突变(图4A、4B)(SEQ ID No.:5&No.:6)，而HY03MM含有N89A及D192A双突变(图5A、5B)(SEQ ID No.:7&No.:8)。
2、蛋白表达分析
四种蛋白的理论分子量分别为：SIRPα-Fc：～128kDa，SIRPαD1-Fc：～82.7kD，HY03M：～82.3kDa，HY03MM：～82.3kDa。通过蛋白电泳(SDS-PAGE)分析发现，在非还原条件下蛋白分子量均大于理论分子量(图6)，这可能是由于蛋白的糖基化所造成的，因为在SIRPαD1区域有一个天冬酰氨连锁的糖基化位点。该位点的不规则糖基化很可能是导致SIRPαD1-Fc在SDS-PAGE胶上还原条件下出现两条带的原因(图6B)，因为去除该糖基化位点以后(HY03M及HY03MM)两条带则变成了一条带(图6C、6D)。
3、靶点结合活性分析
我们利用流式细胞仪首先比较分析了SIRPα-Fc及SIRPαD1-Fc与PC-3细胞的结合活性(图7A)，发现SIRPαD1-Fc的结合活性(EC50＝6.57nM)显著高于SIRPα-Fc(EC50＝12.63nM)。由于以前的研究表明D1区域的糖基化 与否并不影响D1与CD47的结合(Lee WY et al.,2007)，我们将D1区域的N89突变为了N89A(突变体命名为HY03M)，并比较分析了HY03M及SIRPαD1-Fc与CD47的结合活性。结果发现(图7B)，去除糖基化位点以后，HY03M的靶点结合活性(EC50＝0.5nM)显著高于SIRPαD1-Fc(EC50＝1.0nM)。结论：该研究表明，只含有D1区域的蛋白比含有整个膜外端的蛋白靶点活性要好，而去除糖基化位点以后的D1区域，靶点活性更好(靶点活性：HY03M>SIRPαD1-Fc>SIRPα-Fc)。
4、靶点阻断活性分析
利用流式细胞仪我们分析了未标记蛋白(SIRPα-Fc、SIRPαD1-Fc、HY03M、HY03MM)对荧光标记的SIRPα-Fc蛋白与靶点结合活性的影响。结果显示(图8)，四种蛋白均能剂量依赖性地阻断荧光标记蛋白与靶细胞(Jurkat)的结合，其中以SIRPαD1-Fc及HY03M的阻断效应最好(图8下方表格)。
5、HY03M及HY03MM与FcγRs的结合活性及对巨噬细胞吞噬活性的影
在人IgG1-Fc区域第265位点有一个天冬氨酸(D)，在抗体发挥效应功能的过程中发挥关键作用，如果将天冬氨酸突变为丙氨酸(D265A)，IgG几乎完全丧失与FcγRs(FcγRI、FcγRIIA、FcγRIIB、FcγRIIIA)的结合活性(Shields RL,et al.,2001)以及相应的ADCC、CDC等活性。为检验HY03M中的Fc是否参与抗肿瘤活性，我们将HY03M的Fc区域相应位点天冬氨酸突变成了丙氨酸(HY03MM，D192A)of Figure 5B并比较分析了HY03M及HY03MM与FcγRs(FcγRI、FcγRIIA、FcγRIIB、FcγRIIIA)的结合活性。结果表明(图9A)，突变以后的蛋白(HY03MM)与FcγRs的结合活性均显著下降，尤以对FcγRIIA、FcγRIIB、及FcγRIIIA的结合活性下降显著。
为分析突变体对巨噬细胞活性的影响，我们将荧光(CFSE)标记的靶细胞(Jurkat)与巨噬细胞(Raw264.7)分别与HY03M及HY03MM共培养，结果发现(图9B),与隐性对照(IgG)相比，HY03M显著促进巨噬细胞的吞噬活性，而突变体HY03MM则丧失了该活性，与IgG诱导的吞噬活性没有差别。
上述研究表明，单纯阻断CD47与SIRPα的相互作用(比如HY03MM)并不足于诱导巨噬细胞对靶细胞的吞噬活性，必须同时依靠Fc与巨噬细胞膜表面的FcγRs相互作用，才能充分激活巨噬细胞的吞噬活性。
6、HY03M及HY03MM的体内抗肿瘤活性
利用HL60皮下肿瘤模型，我们首先研究了HY03M蛋白的体内抗肿瘤活性。如图10A所示，经VEGF抑制剂治疗的荷瘤小鼠，肿瘤生长并未得到明显的抑制，而HY03M治疗组则显著抑制肿瘤生长，肿瘤大小从治疗开始时的100mm3逐渐萎缩，至实验结束时几乎完全消失了。阴性对照组小鼠的肿瘤体积则随着时间的延长逐渐生长，至结束时肿瘤体积高达1000mm3。该实验结果表明，单独抑制VEGF的活性，对HL60肿瘤没有显著治疗作用，标明HL60肿 瘤的生长对VEGF的依赖性不强。但阻断肿瘤细胞诱导的巨噬细胞吞噬活性的抑制功能，则可增强巨噬细胞对肿瘤细胞的吞噬、并进而消灭肿瘤细胞。
为研究Fc区域是否参与HY03M的抗肿瘤活性，我们利用淋巴瘤(Daudi)模型研究了HY03M、HY03MM、及美罗华(Rituximab)对淋巴瘤的治疗作用。结果表明(图10B)，经HY03M治疗的小组，肿瘤生长显著被抑制(TGI＝72.5％)，抑制效果显著优于美罗华(TGI＝45.6％)，而带有Fc突变的HY03MM对肿瘤生长的抑制活性则大大减弱了(TGI＝26.4％)，表明Fc区域的确参与了HY03M蛋白的抗肿瘤活性。
该实验研究表明，HY03M对肿瘤的治疗作用机理包括两个方面，一方面通过阻断CD47与SIRPα的结合，从而阻断SIRPα传递的抑制性信号而被动激活巨噬细胞；另一方面则通过Fc与FcγRs的结合，主动激活巨噬细胞。
结论
我们的研究表明基因重组Fc融合蛋白SIRPαD1-Fc具有良好的靶点结合活性，其活性显著优于SIRPα-Fc。而去除糖基化位点以后(HY03M)，靶点活性进一步得到提高。体内研究表明HY03M蛋白具有强大的抗肿瘤活性，对于HL60模型，可以达到彻底消灭肿瘤的疗效。该蛋白的主要抗肿瘤作用机制包括两个方面，一方面通过阻断CD47与SIRPα的结合，从而阻断SIRPα传递的抑制性信号而被动激活巨噬细胞；另一方面则通过Fc与FcγRs的结合，主动激活巨噬细胞。这两种机制相互协同，充分激活巨噬细胞对肿瘤细胞的吞噬，而巨噬细胞可进一步将肿瘤抗原交叉递呈给T淋巴细胞(Tseng D,et al.,2013)，最终把肿瘤细胞消灭掉。
如上所述，关于SIRPα-Fc及SIRPαD1-Fc与CD47的结合活性，以前曾有报道(Lee WY et al，2007)，但其二者与靶点CD47的亲和活性并未有差别。而我们的研究结果则表明，SIRPαD1-Fc与CD47的亲和活性(PC-3细胞)(EC50＝6.57nM)显著高于SIRPα-Fc(EC50＝12.63nM)。分析氨基酸序列发现，与Lee WY et al构建的载体相比，我们的SIRPαD1-Fc蛋白在氨基端多了九个氨基酸(SCAWSGVAG)，这可能是导致靶点活性增加的原因之一。进一步研究发现，去除D1区域的糖基化位点(N89A)以后，靶点活性得到进一步增强。另外，通过Fc区域的定点突变(D192A),我们还发现Fc不仅有助于蛋白纯化(通过Protein A亲和层析)及蛋白稳定，而且还参与HY03M的抗肿瘤活性，因为D192A突变体的抗肿瘤活性大大降低。
本发明通过上述一个或多个实施例描述，但可以理解的是本发明不限于实施例，该描述旨在覆盖所附权利要求精神及范围内包括的所有替换、修改及等同。所有的参考文献及文字提及的专利及文献作为参考全部包含于本发明中。
参考文献
1.Gardai SJ,McPhillips KA,Frasch SC,Janssen WJ,Starefeldt A,Murphy-Ullrich JE,Bratton DL,Oldenborg PA,Michalak M,Henson PM.Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte.Cell.2005；123:321–334.
2.Obeid M,Panaretakis T,Joza N,Tufi R,Tesniere A,van Endert P,Zitvogel L,Kroemer G.Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC lightinduced apoptosis.Cell Death Differ.2007；14:1848–1850.
3.Orr AW,Pedraza CE,Pallero MA,Elzie CA,Goicoechea S,Strickland DK,Murphy-Ullrich JE.Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly.J Cell Biol.2003；161:1179–1189.
4.Theocharides,A.P.A.；Jin,L.Q.；Cheng,P.Y.；Prasolava,T.K.；Malko, A.V.；Ho,J.M.；Poeppl,A.G.；Rooijen,N.van；Minden,M.D.；Danska,J.S.；Dick,J.；Wang,J.C.Y.J.Exp.Med.2012 Vol.209 No.10 1883-1899
5.Lee WY et al.Novel Structural Determinants on SIRPa that Mediate Binding to CD47.J Immunol 2007；179:7741-7750.
6.Shields RL et al.High Resolution Mapping of the Binding Site on Human IgG1 for Fc RI,Fc RII,Fc RIII,and FcRn and Design of IgG1 Variants with Improved Binding to the FcgR.JBC.2001,276:6591-6604.
7.Tseng D,et al.Anti-CD47antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.PNAS.2013,110:11103–11108

Claims (17)

  1. 一种重组双功能融合蛋白，包括信号调节蛋白(SIRP)膜外端的Ig样区，与免疫球蛋白的Fc片段连接，其中所述蛋白与CD47结合，从而阻断CD47与巨噬细胞表面SIRP的结合，激活巨噬细胞对肿瘤细胞的吞噬。
  2. 如权利要求1所述的重组双功能融合蛋白，其中所述信号调节蛋白为SIRPα。
  3. 如权利要求2所述的重组双功能融合蛋白，其中所述信号调节蛋白膜外端的Ig样区为SIRPαD1。
  4. 如权利要求1所述的重组双功能融合蛋白，其中所述Fc片段为IgG1的Fc片段。
  5. 如权利要求4所述的重组双功能融合蛋白，其中所述IgG1为人IgG1。
  6. 一种如权利要求1所述的重组双功能融合蛋白的同型二聚体，其中所述同型二聚体包括由一个或多个二硫键连接的两个融合蛋白分子。
  7. 如权利要求1所述的重组双功能融合蛋白，包括与SEQ ID NO.:6具有至少80％、85％、90％、95％、98％或99％相似性的氨基酸。
  8. 如权利要求7所述的重组双功能融合蛋白，包括SEQ ID NO.:6的氨基酸序列。
  9. 一种编码如权利要求7所述的重组双功能融合蛋白的多聚核苷酸。
  10. 一种编码如权利要求8所述的重组双功能融合蛋白的多聚核苷酸。
  11. 一种包含权利要求9所述的多聚核苷酸的表达载体。
  12. 一种包含权利要求10所述的多聚核苷酸的表达载体。
  13. 一种包含如权利要求11所述的表达载体的宿主细胞。
  14. 一种药物组合物，包括如权利要求1所述的重组双功能融合蛋白以及至少一种药物佐剂。
  15. 一种治疗由过度表达CD47引起的疾病的方法，包括向病人或对象给予治疗有效量的如权利要求14所述的药物组合物。
  16. 如权利要求15所述的方法，其中所述疾病选自髓细胞性白血病(AML)、慢性粒细胞白血病(CML)、急性淋巴细胞白血病(ALL)、非霍奇金淋巴瘤(NHL)、多发性骨髓瘤(MM)、膀胱癌、卵巢癌、前列腺癌、肺癌、结肠癌、乳腺癌、胰腺癌以及肾细胞癌。
  17. 如权利要求16所述的方法，其中所述疾病选自克罗恩病、髓过敏性哮喘以及类风湿性关节炎。
PCT/CN2015/094739 2015-04-24 2015-11-16 一种新的重组双功能融合蛋白及其制备和应用 Ceased WO2016169261A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP15889744.7A EP3287470B1 (en) 2015-04-24 2015-11-16 Novel recombinant bi-functional fusion protein and preparation and application therefor
US15/566,724 US10800821B2 (en) 2015-04-24 2015-11-16 Recombinant bi-functional fusion protein and preparation and application therefor
ES15889744T ES2959132T3 (es) 2015-04-24 2015-11-16 Nueva proteína de fusión bifuncional recombinante y preparación y aplicación de la misma
JP2017552177A JP6682554B2 (ja) 2015-04-24 2015-11-16 新規な組換え二機能性融合タンパク質およびその調製および応用
US16/905,262 US20210024598A1 (en) 2015-04-24 2020-06-18 Novel recombinant bi-functional fusion protein and preparation and application therefor
US17/412,445 US20210388043A1 (en) 2015-04-24 2021-08-26 Recombinant bi-functional fusion proteins binding cd47 and fc gamma receptor, preparation and use thereof
US18/492,925 US20250127855A1 (en) 2015-04-24 2023-10-24 Combination Therapy for CMML and MDS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510203619.7A CN106146670B (zh) 2015-04-24 2015-04-24 一种新的重组双功能融合蛋白及其制备和应用
CN201510203619.7 2015-04-24

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/566,724 A-371-Of-International US10800821B2 (en) 2015-04-24 2015-11-16 Recombinant bi-functional fusion protein and preparation and application therefor
US16/905,262 Continuation US20210024598A1 (en) 2015-04-24 2020-06-18 Novel recombinant bi-functional fusion protein and preparation and application therefor
US16/905,262 Division US20210024598A1 (en) 2015-04-24 2020-06-18 Novel recombinant bi-functional fusion protein and preparation and application therefor

Publications (1)

Publication Number Publication Date
WO2016169261A1 true WO2016169261A1 (zh) 2016-10-27

Family

ID=57143738

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2015/094739 Ceased WO2016169261A1 (zh) 2015-04-24 2015-11-16 一种新的重组双功能融合蛋白及其制备和应用
PCT/CN2023/137531 Pending WO2025086418A1 (en) 2015-04-24 2023-12-08 Combination therapy for cmml and mds

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/137531 Pending WO2025086418A1 (en) 2015-04-24 2023-12-08 Combination therapy for cmml and mds

Country Status (6)

Country Link
US (4) US10800821B2 (zh)
EP (1) EP3287470B1 (zh)
JP (1) JP6682554B2 (zh)
CN (1) CN106146670B (zh)
ES (1) ES2959132T3 (zh)
WO (2) WO2016169261A1 (zh)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108484774A (zh) * 2018-03-09 2018-09-04 上海高菲生物科技有限公司 一种SIRPα融合蛋白及其制备方法和用途
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
WO2019080883A1 (en) 2017-10-26 2019-05-02 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF
WO2020029982A1 (en) 2018-08-08 2020-02-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant bifunctional protein targeting cd47 and her2
JP2020505010A (ja) * 2017-01-05 2020-02-20 カール メディカル リミテッド ＳＩＲＰα−４１ＢＢＬ融合タンパク質およびその使用方法
EP3623388A4 (en) * 2017-05-08 2021-08-04 Shanghai JMT-Bio Technology Co., Ltd. BISPECIFIC RECOMBINANT PROTEIN AND ITS USE
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
US11702458B2 (en) 2017-01-05 2023-07-18 Kahr Medical Ltd. PD1-41BBL fusion protein and methods of use thereof
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
US12286466B2 (en) 2018-07-11 2025-04-29 Kahr Medical Ltd. PD1-4-1BBL variant fusion protein and methods of use thereof
US12447195B2 (en) 2021-12-21 2025-10-21 Fbd Biologics Limited Engineered SIRPα variants and methods of use thereof
US12527838B2 (en) 2019-11-27 2026-01-20 ALX Oncology Inc. Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel
US12528866B2 (en) 2018-12-03 2026-01-20 Immuneonco Biopharmaceuticals (Shanghai) Inc. Recombinant protein targeting PD-L1 and VEGF and compositions thereof
US12583926B2 (en) 2023-05-31 2026-03-24 Fbd Biologics Limited CD47/pd-L1-targeting protein complex and methods of use thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
CN108992660B (zh) * 2017-06-06 2023-04-21 深圳市中科艾深医药有限公司 人sDR5-Fc重组融合蛋白作为胰腺炎治疗药物的应用
CN108129572B (zh) * 2018-01-04 2021-01-29 河南大学 人GDF11-Fc融合蛋白在治疗溃疡性结肠炎中的应用
CN110386984B (zh) 2018-04-17 2022-04-22 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN116239698A (zh) * 2019-03-06 2023-06-09 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
CN111909276A (zh) * 2019-05-10 2020-11-10 复旦大学 一种融合蛋白及其用途
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
KR20230018475A (ko) 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
CN112270951B (zh) * 2020-11-10 2022-11-01 四川大学 基于多任务胶囊自编码器神经网络的全新分子生成方法
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN113773401B (zh) 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
CN113831412B (zh) * 2021-10-13 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd24的抗体及其制备和用途
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN113754769B (zh) 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 靶向cd70的抗体及其制备和用途
CN115232207B (zh) * 2022-05-19 2023-06-13 河南大学 抗体-溶菌素（SM-ScFv-Fc-Ly）在治疗变形链球菌感染中的应用
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
JP2025160816A (ja) * 2024-04-10 2025-10-23 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド 古典的ホジキンリンパ腫に対する併用療法
US20250332216A1 (en) * 2024-04-26 2025-10-30 Immuneonco Biopharmaceuticals (Shanghai) Inc. Combination therapy for classic hodkin's lymphoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102257001A (zh) * 2008-12-19 2011-11-23 诺瓦提斯公司 治疗自体免疫和炎性病症的可溶性多肽
CN102596233A (zh) * 2009-05-15 2012-07-18 大学健康网络 用于以SIRPα-CD47的相互作用为靶标治疗血液癌症的组合物和方法
CN104136037A (zh) * 2012-01-17 2014-11-05 小利兰·斯坦福大学托管委员会 高亲和力SIRP-α试剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930706D0 (en) * 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
PL3575326T3 (pl) * 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
JP6355032B2 (ja) * 2014-03-24 2018-07-11 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド 新規組換え二機能性融合タンパク質、それらの調製および使用
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
CN109306017B (zh) * 2018-10-12 2021-02-09 倍而达药业（苏州）有限公司 一种基于SIRP-αD1突变体制备的重组蛋白及应用
ES2973832T3 (es) * 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
KR20230018475A (ko) * 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102257001A (zh) * 2008-12-19 2011-11-23 诺瓦提斯公司 治疗自体免疫和炎性病症的可溶性多肽
CN102596233A (zh) * 2009-05-15 2012-07-18 大学健康网络 用于以SIRPα-CD47的相互作用为靶标治疗血液癌症的组合物和方法
CN104136037A (zh) * 2012-01-17 2014-11-05 小利兰·斯坦福大学托管委员会 高亲和力SIRP-α试剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3287470A4 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696730B2 (en) 2015-08-07 2020-06-30 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
US11639376B2 (en) 2015-08-07 2023-05-02 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
US11208459B2 (en) 2015-08-07 2021-12-28 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
JP7194324B2 (ja) 2017-01-05 2022-12-22 カール メディカル リミテッド ＳＩＲＰα－４１ＢＢＬ融合タンパク質およびその使用方法
JP2020505010A (ja) * 2017-01-05 2020-02-20 カール メディカル リミテッド ＳＩＲＰα−４１ＢＢＬ融合タンパク質およびその使用方法
US11897937B2 (en) 2017-01-05 2024-02-13 Kahr Medical Ltd. SIRPalpha-41BBL fusion protein and methods of use thereof
US11702458B2 (en) 2017-01-05 2023-07-18 Kahr Medical Ltd. PD1-41BBL fusion protein and methods of use thereof
US12331098B2 (en) 2017-01-05 2025-06-17 Kahr Medical Ltd. SIRPalpha-41BBL fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11518810B2 (en) 2017-05-08 2022-12-06 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
US12497456B2 (en) 2017-05-08 2025-12-16 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
EP3623388A4 (en) * 2017-05-08 2021-08-04 Shanghai JMT-Bio Technology Co., Ltd. BISPECIFIC RECOMBINANT PROTEIN AND ITS USE
WO2019080883A1 (en) 2017-10-26 2019-05-02 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF
CN108484774B (zh) * 2018-03-09 2021-11-05 上海高菲生物科技有限公司 一种SIRPα融合蛋白及其制备方法和用途
CN108484774A (zh) * 2018-03-09 2018-09-04 上海高菲生物科技有限公司 一种SIRPα融合蛋白及其制备方法和用途
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
US12286466B2 (en) 2018-07-11 2025-04-29 Kahr Medical Ltd. PD1-4-1BBL variant fusion protein and methods of use thereof
CN112533954A (zh) * 2018-08-08 2021-03-19 宜明昂科生物医药技术（上海）有限公司 靶向cd47和her2的重组双功能蛋白
WO2020029982A1 (en) 2018-08-08 2020-02-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant bifunctional protein targeting cd47 and her2
US12528866B2 (en) 2018-12-03 2026-01-20 Immuneonco Biopharmaceuticals (Shanghai) Inc. Recombinant protein targeting PD-L1 and VEGF and compositions thereof
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
US12527838B2 (en) 2019-11-27 2026-01-20 ALX Oncology Inc. Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
US12447195B2 (en) 2021-12-21 2025-10-21 Fbd Biologics Limited Engineered SIRPα variants and methods of use thereof
US12583926B2 (en) 2023-05-31 2026-03-24 Fbd Biologics Limited CD47/pd-L1-targeting protein complex and methods of use thereof

Also Published As

Publication number Publication date
CN106146670A (zh) 2016-11-23
JP2018512850A (ja) 2018-05-24
US10800821B2 (en) 2020-10-13
EP3287470B1 (en) 2023-07-12
WO2025086418A1 (en) 2025-05-01
US20210388043A1 (en) 2021-12-16
US20250127855A1 (en) 2025-04-24
CN106146670B (zh) 2019-01-15
US20180141986A1 (en) 2018-05-24
US20210024598A1 (en) 2021-01-28
ES2959132T3 (es) 2024-02-20
EP3287470A1 (en) 2018-02-28
EP3287470A4 (en) 2018-10-31
JP6682554B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
JP6682554B2 (ja) 新規な組換え二機能性融合タンパク質およびその調製および応用
JP6355032B2 (ja) 新規組換え二機能性融合タンパク質、それらの調製および使用
CN109641049B (zh) Cd3结合抗体
AU2017439776B2 (en) Bifunctional fusion protein targeting CD47 and PD-l1
JP7035299B2 (ja) 新規組換融合タンパク質、ならびにその調製および使用
UA126384C2 (uk) Антитіло, яке зв'язує cd3
US20220056135A1 (en) Bifunctional anti-pd-1/sirpa molecule
WO2024012457A1 (zh) 三特异性抗体及其用途
EP2966085A1 (en) Antibody IgG1 with a modified heavy chain constant region
US20240182572A1 (en) Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
RU2807216C2 (ru) Антитела, связывающие cd3
KR102956517B1 (ko) 트랜스타이레틴 면역글로불린 융합
RU2779489C2 (ru) Антитела, связывающие cd3
HK40081595B (zh) 三特异性抗体及其用途
EA046884B1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15889744

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017552177

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15566724

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015889744

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE